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The ubiquitin-proteasome pathway (UPP) is the main route of protein degradation in eukaryotic 
cells and aids in regulation of cell cycle and cellular homeostasis.  This robust pathway can also 
be utilized for reverse genetics to accelerate the degradation of otherwise stable cellular target 
proteins.  In this work, we present a generalizable approach for protein knockdown by 
developing chimera proteins, called “ubiquibodies”, which combine the activity of an E3 
ubiquitin ligase with the affinity of designer binding proteins (DBPs).  Specifically, we have 
utilized the modular E3 ubiquitin ligase CHIP and replaced its natural substrate-binding domain 
with antibody mimetic binding domains to create various ubiquibodies.  Next, we optimized the 
chimeric construct expression in E. coli and purified uAbs to test their functional activity in 
vitro.  Ubiquibodies were evaluated for both their target binding and subsequent target 
ubiquitination in vitro.  This was further analyzed using mass spectroscopy to determine 
substrate ubiquitination sites and chain linkages.  Within the eukaryotic cellular context, 
ubiquibodies were tested for their ability to specifically ubiquitinate and degrade their target 
proteins.  Finally, preliminary work was performed using rational design to improve uAb E2 
specificity, ensure flexibility for substrate binding and reduce autoubiquitination.  From this 
foundation, we foresee the ubiquibody technology being a powerful tool to enable the dissection 
of protein function, including post-translational modifications, and the selective degradation of 
proteins that underlie human disease. 
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CHAPTER 1 
INTRODUCTION: HIJACKING THE UBIQUITIN PROTEASOME PATHWAY 
Introduction 
Harnessing the major native pathway of eukaryotic protein degradation has been a goal 
towards enabling cellular protein knockdown since the discovery of the ubiquitin-proteasome 
pathway [1-8].  Unlike reverse genetic tools that function at the DNA and RNA levels, targeted 
proteasomal degradation would allow for fast, highly specific, effective removal of proteins at 
the post-translational level.  This attenuated removal of proteins is greatly desired for the 
amelioration of disease states in which detrimental proteins differ from their benign counterparts 
solely by post-translational modifications such as phosphorylation or glycosylation [9].  
Additionally targeted proteolysis would allow for the continued study in differentiating protein 
functions pre- and post-translational modification.  
Current reverse genetic methods for studying protein functions rely upon depletion of a 
protein by genetic knockout at the genomic level, or gene silencing by antisense 
deoxyoligonucleotides or RNA interference [10]. However, these methods remove all forms of 
the protein of interest regardless of its activity or post-translational state.  Many protein functions 
are regulated intracellularly by post-translational modifications such as small chemical 
modifications (e.g. phosphorylation or glycosylation), protein modifications (e.g. ubiquitination 
or sumoylation) or proteolytic cleavage (e.g. pro-insulin cleavage). Thus, in order to study 
proteins at their functional level, post-translational technologies have been developed to inhibit 
proteins of interest.  Major techniques include chemical inhibitors, high affinity antibody 
mimetic proteins and subcellular localization techniques (e.g. knock sideways); none of which 
actually remove the protein of interest from the cell [11, 12].  To address the desire for post-
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translational knockout, several techniques have been developed which harness the ubiquitin 
proteasome pathway (UPP) for targeted protein degradation. 
The ubiquitin proteasome pathway 
Ubiquitination is a highly conserved post-translational modification involved in almost 
all cellular processes in eukaryotes, whereby proteins are modified by the addition of the small 
76 amino acid protein appropriately named ubiquitin [13].  This modification can lead to sub-
cellular protein trafficking, protein kinase activation, modulation of transcription factor activity, 
synthesis of DNA repair or proteasomal degradation [14].  Of these, ubiquitination leading to 
proteasomal degradation is the most characterized to date, as it was one of the earliest roles of 
ubiquitination identified [13].   
The first step of the ubiquitination process occurs when the ubiquitin activating enzyme 
(E1) activates the C-terminal glycine of ubiquitin by ATP hydrolysis, then transfers the 
adenylated ubiquitin to the active site cysteine of the E1, yielding a reactive E1-ubiquitin 
thioester intermediate (Fig. 1.1) [15].  Upon the formation of an E1-E2 complex, the ubiquitin 
molecule is transferred to a conserved catalytic cysteine in the ubiquitin-conjugating (UBC) 
domain of the E2, ubiquitin conjugating enzyme [14].  Finally the ubiquitin ligase (E3) interacts 
with both the ubiquitin-charged E2 and the substrate protein and facilitates the transfer of 
ubiquitin from the E2 to the ε-amine group of a surface lysine residue on the substrate protein. 
Polyubiquitination (polyUb) or chain elongation occurs through a concerted effort of the E2 and 
E3, though the details of this process have not been fully elucidated [14-16].   
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Figure 1.1 The ubiquitin proteasome pathway (UPP). Natural substrates (S) of the UPP are 
targeted for proteasomal degradation by the concerted activities of three enzymes.  The 
sequential steps of ubiquitin (red) transfer are catalyzed by activating (E1), conjugating (E2), and 
ligase (E3) enzymes. For RING or U-box type E3s, the ubiquitin is transferred directly from the 
E2 to a surface lysine on the substrate protein (as depicted).  Polyubiquitin chains are then 
formed on surface lysines of ubiquitin, which can direct for proteasomal degradation. The 
example shown is the canonical lysine-48 linked chain. Image adapted from Fang & Weisman 
[13]. 
 
 4 
In general, E3s are categorized into two main classes, the HECT (homologous to E6-AP 
COOH terminus) family and the RING (really interesting new gene) family.  HECT ubiquitin 
ligases contain a conserved C-terminal domain (~350 amino acids) which accepts the ubiquitin 
from the E2 onto its own active site cysteine before the final transfer to the target protein.   
Contrastingly, RING ubiquitin ligases act solely as a bridge between the E2 and substrate protein 
(Fig. 1.1). These enzymes are classified by their RING domain made up of eight conserved 
cysteines and histidines that coordinate two zinc ions in a cross-braced manner [13].  Other 
classes of E3s related to the RING family include proteins with a PHD (Plant Homeo Domain), 
B-box, or U-box domain.  For example, in the case of the U-box domain, the RING zinc-binding 
sites are replaced by charged and polar residues engaged in hydrogen-bonding networks required 
for structure and activity [17]. 
Increasing the complexity of ubiquitin modification is the possibility for multi-
monoubiquitination or the formation of polyubiquitin (polyUb) chains; the compilation of which 
are referred to as the ubiquitin code (Fig.1.2). The protein ubiquitin contains seven lysine 
residues itself (K6, K11, K27, K29, K33, K48 and K63) and an N-terminal amine, all of which 
can function as receptor sites for ubiquitination.  Though oftentimes the E2 or E3 is able to 
facilitate chain growth, sometimes the creation of polyUb chains requires a fourth enzyme called 
the ubiquitin elongation enzyme (E4) [15].  Specific chain formations differ in both structure and 
function and can cause various outcomes for the substrate protein, as shown in Figure 1.2 [14].   
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Figure 1.2 The ubiquitin code. Ubiquitin is attached to the ε-amino group of a lysine residue on 
substrate proteins (monoubiquitination). Further ubiquitin modification can occur by multi-
monoubiquitination or the process of chain elongation. The different type of ubiquitin 
modification determines the cellular fate of the modified substrate, though not all ubiquitin chain 
motifs have well understood functions.  Image adapted from Ye & Rape [14, 16] 
 
Generally, the ubiquitin code is divided into two main classes, proteolytic and non-
proteolytic functions [16].  Proteolytic functions include the regulation of proteasomal 
degradation and lysosomal degradation.  For example, Lys48-linked chains, the most abundant 
linkage in all organisms, are the canonical chain linkage for proteasomal degradation [16].  
However, Lys11-linked chains play the significant role of triggering degradation of cell cycle 
regulators during mitosis [18]. Additionally Lys29- and Lys63-linked chains have been 
implicated in proteasomal degradation in more specialized cases, revealing the flexibility of the 
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proteasomal cap proteins which recognize substrates for degradation [16].  Lysosomal 
degradation is generally mediated by monoubiquitination or Lys63-linked chains which target 
membrane proteins for lysosomes.  Alternatively, ubiquitinated protein aggregates can be 
degraded by lysosomes after passing through autophagosomes, as directed by receptors 
recognizing Lys63-linked chains [19].   
The well characterized non-proteolytic functions of ubiquitin modification are generally 
signaled by monoubiquitination, N-terminal or Lys63-linked chain formation [16].  
Monoubiquitination has been shown to recruit protein binding partners and thereby mediate 
protein signaling (e.g. PCNA in DNA repair) [13].  Similarly Lys63-linked chains have been 
shown to regulate protein interactions, such as stabilizing polysomes and promoting translation 
[20]. Alternatively, ubiquitination can interfere with protein-protein interactions (including 
conformational changes) or activate a protein by targeting an inhibitory protein for degradation 
[16].  Finally, ubiquitination is known to regulate protein localization, such as the nuclear 
transport of multi-monoubiquitinated p53 [21].  Thus, while some of the ubiquitin code is well 
understood, the functions of many possible chain formations, including mixed or branched 
chains, are still being investigated [14, 16].   
Harnessing the ubiquitin proteasome pathway 
Since the discovery that a chain of four Lys48-linked ubiquitins could target proteins for 
proteasomal degradation, scientists have been trying to harness this regulated ubiquitin-
proteasome pathway (UPP) for targeted protein silencing [22].  The earliest test of altering the 
UPP was performed in vitro by extending the C-terminus of ubiquitin conjugating enzymes (E2s) 
[1, 2].  The Vierstra group was evaluating the E2 protein domains that determined substrate 
specificity and decided to redirect the UPP by adding non-native protein binding domains to the 
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C-terminus of E2s and testing for the degradation of the binding partner in vitro.  However, 
further studies of the UPP showed that ubiquitin ligases (E3) were the key step in protein 
specificity.  Accordingly, the next manipulation of the UPP was with a ubiquitin ligase fusion 
created while studying the E6 and E7 proteins of oncogenic human papillomavirus (HPV) types 
16 and 18 [7].   Scheffner et al. discovered they could degrade the retinoblastoma protein (pRB) 
in vitro by creating a fusion of the N-terminus of HPV-16 E7, which natively binds pRB, with 
the full-length HPV-16 E6, which natively binds and targets p53 for proteasomal degradation.  
The first successful in vivo redirection of ubiquitination for proteasomal degradation was 
performed by engineering the E3 multimeric protein complex SCF (Skp1, Cullin, F box-
containing proteins) in yeast [8].  Zhou et al. showed that by utilizing the F box-containing 
protein Cdc4p, which is the substrate recognition component, and creating a chimeric protein 
with the known binding partner of a new target protein, that the entire SCF complex could be 
redirected toward degradation of the unnatural target protein. Furthermore they showed that the 
human homolog of Cdc4p, βTrCP could similarly be engineered and directed to selectively 
degrade the hypophosphorylated form of the target protein [8, 23-25].   
Unfortunately, F-box subunits are thought to be constitutively unstable due to 
ubiquitination by the complex, for the specific purpose of enabling rapid remodeling of the SCF 
core [26].  Additionally, the over-expression of F-box chimeras was found to overload the core 
SCF complex and hindered ubiquitination of both native and novel target proteins [25].  A 
simpler E3 chimera protein was created by utilizing the U-box ubiquitin ligase CHIP (carboxyl 
terminus of Hsc70-interacting protein) and fusing it to a known binding partner of c-Myc, a 
proto-oncogene transcription factor [4].  This successful example of a redirected ubiquitin ligase 
proved the potential therapeutic use of protein knockdown in showing the suppression of tumor 
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formation by targeted degradation of c-Myc and was followed by a similar approach for targeted 
degradation of KRAS [27].  However in all of these cases, a pre-existing binding partner was 
required to facilitate the degradation of the targeted protein; thus for each new target, a novel 
engineered ubiquitin ligase would have to be created. 
This shortcoming was recently addressed by Caussinus et al. who created a SCF ligase F-
box protein chimera with a single-domain antibody fragment (i.e., nanobody) specific for green 
fluorescent protein (GFP), which was capable of depleting target GFP fusions [28].  While this 
new development will be widely applicable due to the availability of model organisms with 
genetic GFP fusions, it is unable to target endogenous proteins and unique isoforms of proteins. 
Alternative approaches in redirecting the UPP, which each have their own limitations, have 
linked multiple target proteins, utilized small synthetic ligands for specified binding or fused 
aptamers to an E3 [3, 5, 29].  However, a widely applicable, facile approach for effective protein 
knockdown to be used in reverse genetic studies has yet to be attained.    
Designer binding proteins 
 The current forerunner in inhibiting protein function post-translationally has been the 
development of high affinity designer binding proteins (DBP). DBPs first developed out of 
technologies which utilized the natural diversity, specificity and affinity of antibodies from the 
immune system to label proteins of interest ex vivo for biochemical research purposes (e.g. 
immunoblotting, immunoprecipitation, cell sorting, etc.)  However in order to utilize antibodies 
in vivo, dramatic changes were made to reduce their complexity and size and improve their 
intracellular stability.   
One widely used antibody format is the single-chain Fv (variable-fragment) or scFv 
which is a fusion of the variable domain of the heavy chain (VH) and the variable domain of the 
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light chain (VL) connected by a flexible peptide linker to create a single-chain protein of about 
28 kDa (Fig. 1.3b).  This smaller format maintains the antigen binding site of the antibody which 
is harbored in the six complementary determining regions (CDRs), three each in the variable 
domains of the light and heavy chains.  The CDRs are also known as hypervariable regions in 
that they retain the most diversity of the antibody (Fig. 1.3c & d).  However both the VH and VL 
domains require intramolecular disulfide bonds which are readily destroyed in the intracellular 
reducing environment, thus limiting the applicability of scFvs intracellularly.   
  
Figure 1.3 The scFv antibody fragment. (a) The antibody structure is a tetramer, made up of 
two light and two heavy chains connected by disulfide bonds (S-S). (b) The scFv antibody 
fragment is made by fusing the VH and VL domains using a flexible linker. (c) The antigen 
binding site of an antibody is made up of three CDR domains in each variable domain. (d) The 
diversity of binding in the antibody is made up of the hypervariable regions constituting the six 
CDRs. Thus the scFv format maintains the binding diversity of full-length antibodies. Image 
taken from Lobato & Rabbitts, [30]. 
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To address the intracellular stability issue of scFvs, the concept of intracellular antibodies 
or intrabodies developed.  Selection strategies for intrabodies isolate hits based on both high 
binding affinity and specificity, and the intracellular solubility. One method of identifying 
intrabodies is to add a second round intracellular screen post-phage display reduction of library 
size, such as intracellular antibody capture in yeast [31] or protein-activation in E. coli [32]. 
Alternative approaches utilizing the reducing cytoplasm of E. coli include intracellular ribosome 
display [33] and the hitchhiker mechanism of antigen-intrabody binding export through the twin-
arginine translocation pathway [34].  Finally, various efforts have utilized the framework of 
established intrabodies as a scaffold for developing intrabody libraries [35-37]. 
In the process of creating smaller antibody formats with good affinity and stability, many 
synthetic biology tools were developed to enable the creation of gene libraries and selection 
techniques (e.g. phage display, ribosome display, surface display, protein complementation, etc.) 
[38]. However, with these synthetic technologies the use of the immunoglobulin scaffold itself 
became dispensable and thus protein engineers began to utilize novel binding proteins with the 
goal of improved biophysical properties (e.g. stability, solubility, multi-valency and modification 
capabilities) [39].  One major class of alternative scaffold proteins utilizes repeat protein 
domains such as ankyrin repeats (AR), leucine-rich repeats (LRR), tetratricopeptide repeats 
(TPR), HEAT repeats and armadillo repeats (ARM) [39].  Repeat protein domains are naturally 
found across various protein classes enabling protein-protein interactions and are characterized 
by small repeating structural motifs of 20-50 amino acids [39].  These structural motifs stack 
together to create the binding surface area of the protein, which enables binding specificity to 
evolve by both point mutations and insertion/deletion/shuffling of repeats [40].  As such, the 
modular repeat unit became an attractive scaffold for protein engineering.  One such example is 
 11 
the creation of designed ankyrin repeat proteins (DARPins) with varying numbers of internal 
ankyrin repeats (AR), each with six randomized residues, and capped with consensus N- and C-
terminal ARs which provide stability (Fig. 1.4c) [39, 40].  Interestingly, it was later found that 
jawless vertebrates utilize LRRs to create diversity for their adaptive immune system [41], 
validating the use of repeat motifs for generating synthetic protein binding diversity [42]. 
Recognizing that nature uses many structural motifs for specific protein binding, 
alternatives to repeat-protein scaffolds have also been utilized to create synthetic libraries, such 
as monobodies, lipocalins and affibodies (Fig. 1.4) [43].  A monobody is based on the human 
10th fibronectin type 3 domain (10Fn3) which is structurally similar to the β-sandwich structure of 
the VH domain of an antibody. As such, these domains contain three loops, similar to the CDRs 
of antibodies, which have been diversified to create 10Fn3 libraries (Fig. 1.4a) [44].  However the 
10Fn3 domain does not require disulfide bonds and is devoid of natural free cysteines, making it a 
candidate for both intracellular expression and site specific modification using cysteine 
chemistry.  Another alternative, affibodies, were developed from the highly stable binding 
domain of Staphylococcus aureus protein A which has three α-helices and no disulfide bonds 
[42, 43].  Utilizing knowledge of the native binding interface, 13 surface exposed residues in the 
α-helices were randomized to create a combinatorial library from which novel binding proteins 
were selected [44].   As shown in Figure 1.4, this is divergent from the loop diversity found in 
monobodies and similarly scFv formats.  Lastly, lipocalins have a rigid β-barrel with four 
flexible loops that create an entry to a ligand-binding cavity [44].  This scaffold has the unique 
advantage of selectively binding small molecules in the barrel/loop region.  By randomizing the 
loop residues, novel binders have been isolated for both small molecules and protein-protein 
interactions [42]. Unfortunately, most natural lipocalins have intramolecular disulfide bonds 
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which aid in protein stabilization [43].  
 
Figure 1.4 Alternative scaffold proteins. Each scaffold protein domain is shown as a ribbon 
diagram with residues randomized for library creation highlighted in red. (a) The monobody 
structure shows loop diversity similar to scFv domains, while (b) the affibody utilizes a flat 
surface for binding.  (c) The DARPin repeat scaffold utilizes both surface and loop diversity in 
library creation, while (d) lipocalins have a recessed cavity for binding smaller molecules.  
Images taken from Binz et al. [42]. 
 
While the diversity of designer binding protein scaffolds each have unique advantages, 
all of the aforementioned motifs function by solely binding the protein of interest.  As such, to 
inhibit the target protein the intracellular level of a DBP must be equal to, or exceed, that of the 
target because the target protein may escape the DBP binding.  Furthermore, these DBPs may 
not fully neutralize the functional activity of target proteins, depending on their site specificity 
and size.  Thus, we sought to develop a protein silencing strategy that links a DBP with the cell’s 
natural degradation machinery – the ubiquitin proteasome pathway (UPP) – such that the steady-
state levels of the target protein are systematically reduced. 
Recent developments in targeted protein silencing 
In this work we have developed a generalizable protein knockout method whereby an 
otherwise stable protein of interest is specifically targeted for proteasomal degradation.  We have 
done this by engineering the final step of ubiquitination, namely the E3 ubiquitin ligase, and 
created chimeric proteins called “ubiquibodies” (uAb) which combine the versatile binding 
specificity of DBPs with the ubiquitination activity of a ubiquitin ligase to enable substrate 
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recognition and ubiquitination respectively (Fig. 1.5).  Specifically, we have utilized the modular 
E3 ubiquitin ligase CHIP and replaced its natural substrate-binding domain with DBPs to create 
various ubiquibodies.  Next, we optimized the fusion construct expression in E. coli and purified 
uAbs to test their functional activity in vitro.  Ubiquibodies were evaluated for both their target 
binding and subsequent target ubiquitination in vitro.  This was further analyzed using mass 
spectroscopy to determine substrate ubiquitination sites and chain linkages.  Within the 
eukaryotic cellular context, ubiquibodies were tested for their ability to specifically ubiquitinate 
and degrade their target proteins.  Furthermore, the modularity and generalizability of engineered 
uAbs were tested with multiple DBPs.  Finally, preliminary work was performed using rational 
design to improve uAb E2 specificity, ensure flexibility for substrate binding and reduce 
autoubiquitination.  From this foundation, we see the ubiquibody technology being a powerful 
tool to enable the dissection of protein function, including post-translational modifications, and 
the selective degradation of proteins that underlie human disease. 
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Figure 1.5 Redirecting the ubiquitin proteasome pathway. Schematic of redirecting the 
natural UPP with ubiquibodies (uAb).  Naturally, the E1, E2 and E3 cascade tags substrate 
proteins (S) with polyubiquitin chains (K48 shown here) for proteasomal degradation.  In the 
uAb pathway, the engineered E3*, where the natural substrate binding domain has been replaced 
with a designer binding protein (DBP), ubiquitinates the novel target (T) protein for proteasomal 
degradation. 
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CHAPTER 2 
FUNCTIONAL EVALUATION OF AN ENGINEERED UBIQUITIN LIGASE 
Introduction 
 In order to create an engineered ubiquitin ligase which could be redirected toward any 
cytosolic protein, we started with the soluble, modular E3 ubiquitin ligase CHIP (carboxyl 
terminus of Hsc70-interacting protein).  CHIP is an ideal candidate E3 because it has well 
defined structural domains which are directly linked to functionality.  Specifically, CHIP is 
composed of an N-terminal tetratricopeptide repeat (TPR) domain, a helical linker domain, and a 
C-terminal U-box ligase domain (Fig. 2.1a) [45].  The N-terminal TPR domain is involved in 
substrate recognition and is known to bind heat shock proteins such as Hsc70, Hsp70 and Hsp90 
for which it was discovered and named [46].  As such, CHIP is involved in protein quality 
control by both aiding the folding of proteins in concert with the heat shock proteins or 
determining a substrate is unable to fold properly and thus marking it with ubiquitin for 
proteasomal degradation [47].  The helical linker domain of CHIP, also referred to as a helical 
hairpin or coiled-coil, contributes to protein flexibility which has been found to be essential for 
substrate ubiquitination [48].  Finally the C-terminal U-box domain binds E2 ubiquitin 
conjugating enzymes, enabling CHIP’s E3 ubiquitin ligase activity.  In addition to the defined 
structural domains, CHIP’s natural substrate diversity in concert with heat shock proteins, 
suggested the possibility to further extend it towards non-native substrates for targeted 
proteolysis without disrupting its ubiquitin ligase activity.  
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Figure 2.1 Engineering the E3 ubiquitin ligase CHIP.  (a) The crystal structure of CHIP 
highlighting the functional domains from N- to C-terminus, TPR (tetratricopeptide repeat), HH 
(helical hairpin) and U-box domain taken from Zhang et al. [45].   (b) Linear representation of 
CHIP, CHIP∆TPR and R4-uAb. Numbers refer to amino acid positions from N-terminus (N) to 
C-terminus (C). The proteins are aligned vertically with the coiled-coil (a.k.a. HH) and U-box 
domains of CHIP. CHIP∆TPR is a truncated version of CHIP lacking the TPR domain. R4-uAb 
was designed with an additional Gly-Ser (GS) linker connecting the scFv13-R4 intrabody to 
CHIP∆TPR. 
 
 To redirect CHIP’s ubiquitin ligase activity, we removed the TPR domain, its natural 
substrate binding domain, creating CHIP∆TPR (Fig. 2.1b).  This domain was then replaced with 
a well characterized intrabody scFv13-R4 which binds β-galactosidase (β-gal) (Fig. 2.1).  The 
intrabody scFv13-R4 was originally selected, after four rounds of mutagenesis, for its improved 
cytosolic expression in E. coli [32].  Thus our first antigen-ubiquibody pair for testing was β-
galactosidase and the scFv13-R4-CHIP∆TPR fusion, hereafter referred to as R4-uAb (Fig 2.1b).  
This ubiquibody was first tested for soluble expression in E. coli and then purified to evaluate 
binding and ubiquitination activity in vitro.  Furthermore, functionality of R4-uAb in the 
eukaryotic cellular context with the native UPP was tested to evaluate target ubiquitination and 
degradation efficiency.   
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Results 
Soluble expression and purification of ubiquibodies in E. coli.  Desiring high expression of 
uAbs for the purpose of purification, constructs were created in the medium copy plasmid 
pET28a (Fig. 2.2a) and expressed in the E. coli strain BL21(DE3) which is widely used for 
recombinant protein production [49].  Plasmid construction focused on building in modularity to 
enable facile swapping of DBP genes and thus each genetic unit was flanked with a unique 
restriction enzyme site (Fig. 2.2a). The addition of a Gly-Ser (GS) linker connecting the scFv13-
R4 intrabody to CHIP∆TPR was also found to improve cytoplasmic expression (Fig. 2.2b).  In 
order to mediate both 6xHis purification and facile immunoblotting (i.e. avoiding recognition of 
multiple 6xHis tagged proteins), a double epitope tag was tested at N- and C-terminal locations 
(Fig 2.2b). While tag locations had minimal affect on scFv13-R4 or CHIP alone, on the R4-uAb 
fusion, the C-terminal tag was significantly more stable (Fig 2.2b).  Soluble expression of 
ubiquibodies compared to wild-type CHIP, CHIPΔTPR and scFv13-R4 showed an overall 
decrease in expression, but reveal that the fusion protein is stable and soluble (Fig. 2.2c).  
Furthermore, the expression of R4-uAb highlights the need for DBPs with intracellular stability 
as it can be compared to scFv13-uAb, a fusion with the parental scFv13 clone, which was not 
optimized for intracellular expression [32], and which could not be detected (Fig. 2.2c).  
Additional control constructs of R4-uAb include the point mutant R272A which is a U-box 
domain substitution known to inhibit E2 binding [50] and a non-specific uAb made with the 
intrabody D10 which binds the bacteriophage capsid protein gpD [51] (Fig. 2.2c).  Each of these 
constructs was expressed and purified from the E. coli strain BL21(DE3) for in vitro functional 
evaluation (Fig 2.2d). 
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Figure 2.2 Expression of chimera proteins in E. coli. (a) Plasmid map of pET28a-uAb for 
expressing ubiquibodies in bacteria. DNA encoding designer binding proteins (DBPs) is cloned 
as a fusion with human CHIP that includes the coiled-coil and U-box domains but not the TPR 
domain (CHIPΔTPR). A flexible Gly-Ser linker (GSGSG) is introduced after the DBP. FLAG 
(F) and 6xHis (H) epitope tags are introduced after CHIPΔTPR. (b & c) Western blot analysis of 
cell lysates derived from E. coli strain BL21(DE3) expressing full-length scFv13-R4, CHIP, 
R4uAb direct fusion and R4-uAb fusion with the Gly-Ser linker (b).  N- versus C-terminal 
double epitope tags are also denoted. (c) Comparison of different scFv uAb constructs made in 
pET28a-uAb (a). Specifically, parental scFv13-uAb is compared to intrabody R4-uAb.  Also the 
control R272A point mutant which interferes with E2 binding and a non-specific scFv D10-uAb 
are included.  An equivalent amount of total protein was loaded in each lane and anti-FLAG 
antibodies were used to detect the expressed proteins. (c) Coomassie stained SDS-PAGE 
analysis of different proteins from (b) following Ni2+-affinity chromatography. 
 
Functional testing of anti-β-gal ubiquibody in vitro. First we tested the binding affinity of 
purified R4-uAb compared to the scFv13-R4 alone and found that binding to β-gal was unaltered 
(Fig. 2.3a), indicating that fusion to CHIP∆TPR does not affect antigen-binding activity of the 
intrabody domain. Additionally the R272A substitution in the U-box domain had no affect on β-
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gal affinity.  In contrast, no significant β-gal binding was seen for CHIP∆TPR or the control 
D10-uAb (Fig. 2.3a).   
 
Figure 2.3 Redirecting a ubiquitin ligase towards a non-native substrate. (a) Binding activity 
of purified R4-uAb measured by ELISA with β-gal as antigen. The intrabody scFv13-R4 served 
as a positive control while CHIP∆TPR and D10-uAb served as negative controls. Also tested 
was R4-uAbR272A, a derivative of R4-uAb carrying a point mutation in the U-box domain that is 
known to block the interaction between CHIP and the E2 enzyme, UbcH5α. (b) At the indicated 
times, in vitro ubiquitination reactions were stopped by boiling and immunoblotted with anti-β-
gal antibodies. Protein bands corresponding to β-gal and the various β-gal-ubiquitin conjugates 
as well as the molecular weight of the marker bands (MW) are indicated. An equivalent amount 
of total protein was loaded in each lane. 
 
Next, we performed in vitro ubiquitination assays with purified components, including 
R4-uAb as the E3 enzyme and β-gal as the target (note that β-gal has 20 lysine residues that 
serve as potential ubiquitin attachment sites [52]). UbcH5α was used as the E2 enzyme because 
it has previously been shown to function with CHIP in vitro [48]. High molecular weight bands 
corresponding to ubiquitinated β-gal were observed, especially over longer incubation times 
(Fig. 2.3b), which was characteristic of CHIP-mediated polyubiquitination of its native targets 
[48]. These results confirm that the CHIP∆TPR domain retained E3 ligase activity in the context 
of the chimera. Additionally, ubiquitination only proceeded when all pathway components were 
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included in the reaction (Fig. 2.4), indicating that R4-uAb activity was dependent on a complete 
ubiquitination pathway. Similar polyubiquitination was detected with an antibody specific for 
K48-linked polyUb chains (Fig. 2.4), confirming the presence of ubiquitin linkages that are 
known to signal proteasomal degradation [53]. Importantly, when reactions were performed with 
scFv13-R4, CHIP∆TPR, or the non-specific D10-uAb, there was no detectable ubiquitination of 
β-gal (Fig. 2.4). Likewise, R4-uAbR272A which should not interact with the E2 UbcH5α, failed to 
conjugate ubiquitin (Fig. 2.4) even though it was capable of binding β-gal (Fig. 2.3a).  
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Figure 2.4 In vitro ubiquitination of β-gal. Ubiquitination of β-gal was evaluated in the 
presence (+) or absence (-) of each ubiquitin pathway component, namely ubiquitin (Ub), E1, E2, 
and R4-uAb as E3. Controls included scFv13-R4, CHIP∆TPR, R4-uAbR272A, and D10-uAb. An 
equivalent amount of total protein was added to each lane. Immunoblots were probed with anti-
β-gal, anti-ubiquitin, anti-K48, and anti-6xHis antibodies. Protein bands corresponding to β-gal, 
mono-ubiquitinated β-gal (*) and β-gal-ubiquitin conjugates as well as the molecular weight of 
the marker bands (MW) are indicated. The results are representative of at least three replicate 
experiments. 
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Identification of lysine residues modified by anti-β-gal ubiquibody. We next investigated 
which lysine residues were ubiquitinated by our engineered R4-uAb fusion. In vitro 
ubiquitination of β-gal was monitored by SDS-PAGE and the formation of higher molecular 
weight species was clearly evident in the region of the gel where ubiquitinated β-gal would be 
expected to resolve (Fig. 2.5). We also detected R4-uAb-ubiquitin conjugates, consistent with 
earlier reports showing autoubiquitination of CHIP and CHIP fusions [48]. However at early 
time points, these were at lower molecular weight regions of the gel. Therefore, bands on the gel 
corresponding to modified β-gal after 15 min of ubiquitination (delineated in red), were excised, 
digested with trypsin, and analyzed by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) (Fig. 2.5).  
 
 
Figure 2.5 In vitro ubiquitination by engineered ubiquibodies. Coomassie-stained SDS-
PAGE analysis of R4-uAb-mediated ubiquitination reactions in the presence and absence of E. 
coli β-gal at various times after initiation. Protein bands corresponding to unmodified β-gal, R4-
uAb, various ubiquitin conjugates and the molecular weight of the marker bands (MW) are 
indicated. Trypsin digests and subsequent LC-MS/MS analysis was performed on the proteins 
delineated by the red box. 
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Peptides corresponding to 80% of the β-gal sequence were identified using Mascot 
software, suggesting good coverage of the entire protein sequence. Trypsin digestion of a 
ubiquitinated protein leaves the C-terminal Gly-Gly of ubiquitin attached to the ubiquitinated 
lysine residue. Therefore, the MS data was searched for such modification of β-gal lysines and 
five modified residues were identified:  K348, K518, K662, K774, and K775. All five lysines are 
solvent accessible [52] (Fig. 2.6a), consistent with the location of ubiquitin attachment sites on 
native substrates Hsp70 and Hsp90 [54]. The MS/MS spectra of two β-gal peptides that include 
the identified ubiquitination sites K774 and K775 are depicted in Figures 2.6b and c, 
respectively.  
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Figure 2.6 Lysine residues of β-gal modified by ubiquitin. (a) Mapping of ubiquitinated 
lysines (red balls) onto crystal structure of a single β-gal monomer (blue). All identified lysines 
are solvent exposed in the homotetramer (grey) model generated in PyMOLTM using PDB 1DP0. 
MS/MS spectra of representative β-gal peptides (b) 762-QSGFLSQMWIGDKK-775 and (c) 
775-KQLLTPLR-782, containing Gly-Gly modified (ubiquitinated) lysine residues. Modified 
lysine residues are labeled with GG and correspond to (a) K774 and (b) K775 in β-gal. 
Fractionation of the peptides into b and y ions was performed, and the corresponding peaks are 
labeled on the spectra. The y-axis, relative abundance, was normalized to the most abundant 
identified peptide fragment. 
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Peptides corresponding to 95% of the ubiquitin sequence were also identified in the mass 
spectrometry analysis. Specifically, lysine residues K6, K11, K48, and K63 within ubiquitin 
were found to be modified in peptides isolated from our high molecular weight samples, 
suggesting these chain linkages in the polyubiquitination of β-gal by R4-uAb. These same chain 
linkages were previously observed on natural substrates that had been ubiquitinated by full-
length CHIP in vitro [54]. The MS/MS spectra of two ubiquitin peptides that include the 
identified ubiquitination sites K48 and K63 are depicted in Figure 2.7a and b, respectively. It is 
worth noting that while K48-linked chains are considered the canonical linkage associated with 
targeting proteins for proteasomal degradation, all linkages identified here including K6, K11, 
and K63 have been implicated as targeting signals for the 26S proteasome [55, 56]. 
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Figure 2.7 Ubiquitin lysine residues modified by another ubiquitin. MS/MS spectra of 
representative ubiquitin peptides (a) 43-LIFAGKQLEDGR-54 and (b) 55-
TLSDYNIQKESTIHLVLR-72 containing Gly-Gly modified (ubiquitinated) lysine residues. 
Modified lysine residues are labeled with GG and correspond to (a) K48 and (b) K63 in 
ubiquitin. Fractionation of the peptides into b and y ions was performed, and the corresponding 
peaks are labeled on the spectra. Peptide fragment ions that have a +2 charge or lost an NH3 
group are indicated with 2+ and -NH3, respectively. The y-axis, relative abundance, was 
normalized to the most abundant identified peptide fragment.  
 
Ectopic co-expression of β-gal and R4-uAb.  We next investigated whether R4-uAb-mediated 
ubiquitination would result in β-gal depletion by the UPP in mammalian cells. First, HEK293T 
cells were transiently co-transfected with pcDNA3-based plasmids encoding E. coli β-gal and the 
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R4-uAb, where each construct was under control of the strong human cytomegalovirus (CMV) 
promoter. Next, cellular β-gal levels were measured by immunoblotting cell lysates collected 24 
h post-transfection. When HEK293T cells were co-transfected with pcDNA3-β-gal and 
increasing amounts of pcDNA3-R4-uAb, the β-gal levels were systematically reduced to as low 
as 2% of the steady-state levels measured in cells transfected with only the pcDNA3-β-gal 
plasmid (Fig. 2.8). In contrast, no reduction in β-gal expression was observed following co-
transfection with the pcDNA3-D10-uAb or pcDNA3-scFv13-R4 plasmids (Fig. 2.8). 
Interestingly, cells co-transfected with R4-uAbR272A exhibited an intermediate level of β-gal 
expression indicating that this point mutation in CHIP’s U-box domain may inhibit some but not 
all E2 interactions in vivo. Importantly, the levels of a housekeeping protein, GAPDH, and a 
native binding partner of full-length CHIP, Hsp70, were not affected by co-transfections (Fig. 
2.8).  
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Figure 2.8 R4-uAb-mediated proteolysis of β-gal in mammalian cells. Immunoblots of 
extracts prepared from HEK293T cells transfected with pcDNA3-β-gal alone (β-gal only) or co-
transfected with pcDNA3-β-gal along with one of the following: pcDNA3-R4-uAb, pcDNA3-
D10-uAb, pcDNA3-R4-uAbR272A, or pcDNA3-scFv13-R4. The triangle indicates increasing 
amounts of pcDNA3-R4-uAb plasmid DNA used to transfect cells. The percentages of β-gal 
remaining in each sample were quantitated by densitometry scanning and are indicated. An 
equivalent amount of total protein was loaded in each lane. Blots were probed with antibodies 
specific for β-gal, 6xHis, GAPDH and Hsp70 as indicated. The immunoblot results are 
representative of at least three replicate experiments. 
 
Evaluating β-gal knockdown by microscopy. Next we began evaluating co-transfected 
HEK293T cells with microscopy techniques to further investigate the β-gal knockdown shown 
by immunoblotting.  A pcDNA3-β-gal-eGFP fusion was created in order to perform live cell 
imaging at various time points post-transfection.  At 8 h post-transfection, β-gal-eGFP 
expression was seen diffuse throughout the cellular cytoplasm (Fig. 2.9 β-gal only).  However, 
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when pcDNA3-β-gal-eGFP was co-transfected with pcDNA3-R4-uAb, fluorescent foci were 
seen which were not detected in control co-transfections with pcDNA3-scFv13-R4 nor pcDNA3-
D10-uAb (Fig. 2.9).   
 
Figure 2.9 Fluorescence microscopy of β-gal-eGFP fusion.  HEK293T cells were transfected 
with 0.5 µg pcDNA3-β-gal-eGFP alone (β-gal-eGFP only) or co-transfected with 1.25 µg 
pcDNA3-R4-uAb, pcDNA3-scFv13-R4 or pcDNA3-D10-uAb as indicated.  Live cell images 
were taken at 8 h post-transfection using a 40x objective. The scale bar shown is 20 µm. 
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To determine if foci were an artifact of the β-gal-eGFP fusion, β-gal expression was next 
evaluated using immunofluorescent staining at 24 h post-transfection (Fig. 2.10).  Again, when 
HEK293T cells were transfected with pcDNA3-β-gal alone, β-gal expression was diffuse 
throughout the cytoplasm of the cells, but when co-transfected with the pcDNA3-R4-uAb, foci 
were detected (Fig. 2.10).   
 
Figure 2.10 Immunofluorescent staining of 293T cells transfected with β-gal. HEK293T 
cells transfected with 0.5 µg pcDNA3-β-gal alone or co-transfected with 1.0 µg pcDNA3-R4-
uAb as indicated. Cells were fixed at 24 h post-transfection, permeabilized and stained with anti-
β-gal primary antibodies followed by a secondary conjugated with Alexa Fluor 568. Images were 
taken using a 5x objective and the scale bar shown is 40 µm. 
 
One possible explanation for the foci was that β-gal was being partitioned to the insoluble 
fraction.  To evaluate this possibility, HEK293T cells were transfected as in Figure 2.8 except 
that insoluble fractions were then solubilized in 2% SDS by boiling and loaded equivolume with 
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the soluble lysates for detection by immunoblotting (Fig. 2.11).  Cellular fractionations revealed 
that both β-gal and β-gal-eGFP were partitioning to the insoluble fractions when cells were co-
transfected with the ubiquibody (Fig. 2.11).  Additionally the ubiquibody itself was found 
partitioning to the insoluble fraction (anti-6xHis).  For these analyses, GAPDH served as a 
loading control for the soluble fractions and ensured that the insoluble fractions did not contain 
appreciable amounts of soluble cytosolic proteins (Fig. 2.11). 
 
Figure 2.11 Evaluating insoluble fractions from 293T cells. Immunoblots of soluble and 
insoluble extracts prepared from HEK293T cells transfected with pcDNA3-β-gal alone (β-gal 
only), pcDNA3-β-gal-eGFP alone (β-gal-eGFP only), or co-transfected with pcDNA3-R4-uAb. 
An equivalent amount of total protein was loaded in each soluble lysate lane and equivolume 
samples were loaded for the insoluble fractions. Blots were probed with antibodies specific for β-
gal, 6xHis and GAPDH as indicated and molecular weight (MW) markers are labeled. 
 
Results from the insoluble fractionation revealed that the reduction in β-gal levels may be 
a combined effect of UPP degradation and partitioning to the insoluble fraction.  In order to 
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investigate this phenomenon, we sought to determine if the partitioning was due to the high 
expression level of ubiquitinated β-gal, co-expression with an exogenous protein (i.e. non-
specific to ubiquibody interactions), or over-expression of the specific uAb binding to β-gal.  To 
address each of these theories, HEK293T cells were transfected with 5-fold (Fig. 2.12a) and 10-
fold (Fig. 2.12b) less pcDNA3-β-gal and a broad range gradient of pcDNA3-R4-uAb DNA (Fig. 
2.12).  From these gradients, it was evident that at lower levels of transfection, less β-gal and less 
R4-uAb partitioned to the insoluble fractions. Furthermore, by reducing the pcDNA3-β-gal 
transfection 10-fold, partitioning of β-gal to the insoluble fraction was only detectable with 
prolonged exposure and R4-uAb was undetectable.  Additionally, the controls pcDNA3-scFv13-
R4 and pcDNA3-D10-uAb were included at the highest level of co-transfection and revealed no 
partitioning of β-gal to the insoluble fraction, revealing that the phenomenon was dependant on 
cognate ubiquibody co-transfection (Fig. 2.12a and b, right hand lanes). 
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Figure 2.12 Reducing co-transfection levels of β-gal and R4-uAb. Immunoblots of extracts 
prepared from HEK293T cells transfected with pcDNA3-β-gal alone (β-gal only) or co-
transfected with pcDNA3-β-gal and one of the following: pcDNA3-R4-uAb, pcDNA3-D10-uAb 
or pcDNA3-scFv13-R4. The triangle indicates increasing amounts of pcDNA3-R4-uAb plasmid 
DNA used to transfect cells. An equivalent amount of total protein was loaded in each soluble 
fraction lane and equivolume insoluble fractions were loaded. Blots were probed with antibodies 
specific for β-gal, 6xHis and GAPDH as indicated.  
  
Ectopic expression of R4-uAb mediates proteasomal degradation. Having reduced the 
overall expression of β-gal in HEK293T cells such that it was no longer being partitioned to the 
insoluble fraction, R4-uAb-mediated silencing was re-evaluated. HEK293T cells were 
transiently transfected with pcDNA3-β-gal only (at 0.05 µg DNA) or co-transfected with 
pcDNA3-R4-uAb (0.05-1.25 µg DNA).  Cellular β-gal levels were measured by immunoblotting 
(Fig. 2.13) and by determining β-gal activity 24 h post-transfection (Fig. 2.15). When HEK293T 
cells were co-transfected with pcDNA3-β-gal and increasing amounts of pcDNA3-R4-uAb, the 
β-gal levels were systematically reduced to as low as 3% of the steady-state levels measured in 
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cells transfected with only the pcDNA3-β-gal plasmid (Fig. 2.13). In contrast, no reduction in β-
gal expression was observed following co-transfection with pcDNA3-D10-uAb or pcDNA3-
scFv13-R4 plasmids (Fig. 2.13). Interestingly, cells co-transfected with R4-uAbR272A again 
exhibited an intermediate level of β-gal expression (Fig. 2.13) as previously shown (Fig. 2.8). 
Importantly, the levels of a housekeeping protein, GAPDH, and a native binding partner of full-
length CHIP, Hsp70, were not affected by co-transfections (Fig. 2.13).  Additionally, evaluation 
of insoluble fractions confirmed that β-gal depletion was not due to cellular partitioning (Fig. 
2.13).  
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Figure 2.13 R4-uAb-mediated proteolysis of β-gal in HEK293T cells. Immunoblots of 
extracts prepared from HEK293T cells transfected with pcDNA3-β-gal alone (β-gal only) or co-
transfected with one of the following: pcDNA3-R4-uAb, pcDNA3-D10-uAb, pcDNA3-R4-
uAbR272A, or pcDNA3-scFv13-R4. The triangle indicates increasing amounts of pcDNA3-R4-
uAb plasmid DNA used to transfect cells. An equivalent amount of total protein was loaded in 
each lane. Blots were probed with antibodies specific for β-gal, 6xHis, GAPDH and Hsp70 as 
indicated. The immunoblot results are representative of at least three replicate experiments.  
 
Similar results for co-transfection of pcDNA3-β-gal with pcDNA3-R4-uAb were obtained in 
BHK21 and COS-7 cells (Fig. 2.14), indicating that targeted protein silencing by engineered 
ubiquibodies is transferable between different cell lines.  Notably, in both BHK21 and COS-7 
cell lines, the one-to-one ratio of co-transfection with pcDNA3-β-gal and pcDNA3-R4-uAb 
(lowest dosage) was as effective at silencing β-gal as higher ratios of ubiquibody. Additionally, 
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higher amounts of pcDNA3-R4-uAb appeared to partition some β-gal to the insoluble fractions 
(Fig. 2.14 insoluble) even at the reduced pcDNA3-β-gal transfection level. Thus the underlying 
physiological explanation for sub-cellular partitioning may still be significant.   
 
Figure 2.14 R4-uAb-mediated proteolysis of β-gal in different cell lines. (a) Immunoblots of 
extracts prepared from BHK21 (left) and COS-7 (right) cells transfected with pcDNA3-β-gal 
alone (β-gal only) or co-transfected with pcDNA3-β-gal along with one of the following: 
pcDNA3-R4-uAb, pcDNA3-scFv13-R4, or pcDNA3-D10-uAb. The triangle indicates increasing 
amounts of pcDNA3-R4-uAb plasmid DNA used to transfect cells. An equivalent amount of 
total protein was loaded in each lane. Blots were probed with antibodies specific for β-gal, 6x-
His and GAPDH as indicated. The immunoblot results are representative of two replicate 
experiments.  
 
In all three cell lines, β-gal knockdown was also detectable using β-gal activity assays (Fig. 
2.15).  Biological triplicate co-transfections using the best knockdown levels in each cell line 
(i.e. highest level of pcDNA3-R4-uAb in HEK293T and lowest level of pcDNA3-R4-uAb in 
BHK21 and COS-7) showed reproducible, significant knockdown compared to transfection with 
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pcDNA3-β-gal alone and control co-transfections with either pcDNA-scFv13-R4 or pcDNA3-
D10-uAb (Fig. 2.15).   
 
 
Figure 2.15 β-gal activity assay detecting knockdown in multiple cell lines. β-gal activity 
measured in samples transfected as described in Figures 2.13 and 2.14. In HEK293T cells the 
highest level of co-transfection was tested, whereas in COS-7 and BHK21, the lowest co-
transfection level was used (control co-transfections were performed with the same amount of 
DNA). Data was normalized to the signal for the β-gal only control and is expressed as the mean 
± standard deviation of the mean (SDM) of biological triplicates including error propagation 
from the activity assay absorbance and the total protein assay used in calculations.   
 
Finally, to confirm that R4-uAb specifically binds and ubiquitinates β-gal in vivo, β-gal 
interactions were evaluated using a pull-down assay. HEK293T cells were transiently transfected 
with pcDNA3-R4-uAb or pcDNA3-β-gal alone, or co-transfected with pcDNA3-β-gal and 
pcDNA3-R4-uAb, pcDNA3-scFv13-R4 or pcDNA3-D10-uAb.  Each ubiquibody or scFv control 
contains a C-terminal 6xHis tag which was then used to isolate these proteins using Ni2+ affinity 
magnetic agarose beads. As expected, both R4-uAb and scFv13-R4, but not D10-uAb, co-
precipitated β-gal (Fig. 2.16). Furthermore, high molecular weight proteins co-precipitated by 
R4-uAb were observed to cross-react with an anti-ubiquitin antibody (Fig. 2.16), suggesting that 
ubiquitinated β-gal was present in cells co-transfected with pcDNA3-R4-uAb. These results 
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suggest that β-gal depletion in mammalian cells results from specific target binding and 
ubiquitination by the engineered R4-uAb. 
 
Figure 2.16 Co-precipitation of ubiquitinated β-gal in HEK293T cells. Immunoblots of pull-
down samples or extracts prepared from HEK293T cells transfected with pcDNA3-R4-uAb 
alone (R4-uAb only), pcDNA3-β-gal alone (β-gal only) or co-transfected with pcDNA3-β-gal 
along with one of the following: pcDNA3-scFv13-R4, pcDNA3-R4-uAb, or pcDNA3-D10-uAb. 
Pull-down was performed by subjecting extracts to Ni-NTA magnetic agarose beads followed by 
immunoblotting with antibodies specific for β-gal, ubiquitin and 6x-His as indicated. An 
equivalent amount of total protein was loaded in each lane, as confirmed by immunoblotting 
with anti-GAPDH antibodies. Immunoblots are representative of three replicate experiments. 
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Discussion 
Thus far, we have redirected the E3 ubiquitin ligase CHIP to target an otherwise stable 
protein, β-galactosidase, for degradation by the ubiquitin proteasome pathway.  In creating this 
ubiquibody, we have exploited the modular architecture and intrinsic flexibility of CHIP [48].  
Owing to the catalytic nature of ubiquitination, a single ubiquibody molecule has the potential 
for elimination of numerous copies of its target protein. This represents a major advantage over 
target inactivation using binding proteins alone, which require a one-to-one stoichiometric ratio 
(or greater) with their target because there are no elimination pathways for binding protein-target 
complexes. 
While sub-cellular partitioning of β-gal in the presence of the ubiquibody was 
unexpected, the biological explanation may be elegantly simple.  CHIP has been shown to 
interact with the chaperone-assisted selective autophagy pathway (CASA) [57].  Furthermore, it 
is known that K63-linked polyUb chains are recognized by CASA receptors such as p62 which 
then target aggregated proteins for autophagy and lysosomal degradation [58].  Notably, the 
R272A point mutation which was used to inhibit E2 interaction may not inhibit CHIP’s 
interactions with the Uev1a/Ubc13 heterodimer E2 which forms K63-linked chains in concert 
with wild-type CHIP [59]. Thus while further experimentation will be required to prove whether 
the insoluble partitioning was due to autophagy pathway processing, it could be a valuable 
alternate approach for targeted degradation of oligomeric (such as β-gal which forms a tetramer) 
or aggregation prone substrates.  To further investigate this phenomenon, immunofluorescent 
labeling could be used to label co-transfected cells for both β-gal and standard autophagy or 
lysosomal markers (i.e. LC3B or cathepsin L respectively). 
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In this work, we have attained significant knockdown in three different cell lines 
(HEK293T, BHK21 and COS-7) using transient co-transfection to deliver target and ubiquibody 
proteins.  However, it is anticipated that infection with different doses of recombinant 
adenoviruses expressing ubiquibody genes could lead to complete ablation of target protein 
levels by overcoming the lower transfection efficiency that is typically associated with transient 
co-transfection [23].  Furthermore, we have so far only addressed the ubiquitination of one novel 
substrate, namely β-galactosidase.  Thus the next step towards developing a generalizable protein 
knockdown technology is to swap the scFv13-R4 domain with other designer binding proteins 
(DBPs) and evaluate ubiquibody functionality.  
Materials and Methods 
Plasmid construction. Full-length human CHIP (a gift from Cam Patterson) was PCR amplified 
for cloning into pET28a(+) using 5’ NcoI and 3’ SalI restriction sites. DNA encoding a double 
tag of FLAG-6xHis was created by dimerizing primers with a 5' SalI overhang and a 3’ HindIII 
overhang. Double ligation was performed to insert the CHIP PCR product and phosphorylated 
primer dimer between NcoI and HindIII sites in pET28a(+), yielding plasmid pET28a-CHIP. To 
create truncated CHIP∆TPR, DNA corresponding to amino acids 128-303 of human CHIP was 
PCR amplified with introduction of a 5’ NcoI site and a 3’ SalI site. Double ligation was 
performed as above to insert this product along with the primer dimer into pET28a(+), yielding 
pET28a-CHIP∆TPR. The genes encoding scFv13 and scFv13-R4 (a gift from Pierre Martineau) 
were PCR amplified and again each was double ligated into pET28a(+) with the above primer 
dimer, yielding the control plasmids pET28a-scFv13 and pET28a-scFv13-R4, respectively. To 
create CHIP∆TPR fusions, PCR was used to introduce an EcoRI site followed by a short, 
flexible linker of GSGSG to the 5’ end of CHIP∆TPR. In parallel, each of the DBPs including 
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scFv13, scFv13-R4, and the scFv D10 (a gift from Andreas Plückthun) was PCR amplified with 
a 5’ NcoI site and 3’ EcoRI site. Double ligation was then used to insert each scFv along with the 
GSGSG linker-CHIP∆TPR product between the NcoI and SalI sites of pET28a-CHIP, yielding 
pET28a-scFv13-uAb, pET28a-R4-uAb, and pET28a-D10-uAb (Fig. 2.2a). The R272A point 
mutation was introduced into pET28a-R4-uAb using a QuikChange site-directed mutagenesis kit 
(Stratagene). For expression in eukaryotic cells, the above constructs were PCR amplified from 
their pET28a(+) backbones using primers that introduced a Kozak sequence at the start codon as 
well as a 5’ HindIII site and a 3’ XbaI site. The resulting PCR products were then cloned 
between the HindIII and XbaI sites of plasmid pcDNA3. The target substrate protein β-gal was 
PCR amplified using primers that introduced a Kozak sequence at the start codon as well as 5’ 
XhoI and a 3’ XbaI site and cloned in the corresponding sites of pcDNA3. For microscopy 
studies, the β-gal-eGFP fusion was created by PCR amplifying β-gal with a 5’ XhoI site and a 3’ 
BamHI site which was then ligated into pcDNA3.1(+)-α-synuclein-eGFP (a gift from Anne 
Messer) replacing α-synuclein to create pcDNA3.1(+)-β-gal-eGFP. 
Protein expression and purification.  All purified proteins were obtained from cultures of E. 
coli BL21(DE3) cells grown in 500 mL of Luria-Bertani (LB) medium. Expression was induced 
with 0.1 mM IPTG when the culture density (Abs600) reached 0.6-0.8 and proceeded at 30°C for 
6 h, after which cells were harvested by centrifugation at 4,000xg for 20 min at 4°C. The 
resulting pellets were stored at -80°C overnight.  Thawed pellets were resuspended in 15 mL 
buffer A (20 mM sodium phosphate, 0.5 M NaCl and 20 mM imidazole, pH 7.4) and lysed with 
a high-pressure homogenizer (Avestin EmulsiFlex C5).  Lysates were cleared by centrifugation 
at 20,000xg for 20 min at 4°C and then subjected to Ni2+-affinity purification with an ÅKTA 
FPLC using a 1-ml HisTrap column (GE Healthcare). Samples were washed with 10% buffer B 
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(20 mM sodium phosphate, 0.5 M NaCl and 500 mM imidazole, pH 7.4) before elution with 
50% buffer B. Purified proteins were desalted over a 5-mL HiTrap column equilibrated with 
ubiquitination reaction buffer (20 mM MOPS, 100 mM KCl, 1 mM DTT, 5 mM MgCl2, pH 7.2).   
Enzyme-linked immunosorbent assay (ELISA).  For ELISA, a previously established protocol 
was used to detect binding to β-gal [33], with slight modification. Briefly, a 96-well EIA plate 
was coated with 100 μL β-gal (Sigma) at 10 μg/mL overnight at 4°C. The plate was then washed 
three times with 200 μL PBST (1x PBS + 0.1% Tween20) per well for 5 min with shaking and 
blocked with 250 μL PBS with 3% milk per well at room temp, slowly mixing for 3 h. Following 
three washes as above, purified protein samples were introduced in blocking buffer as serial 
dilutions with 60 μL per well and incubated at room temp slowly mixing for 1 h. Three washes 
were used to remove non-bound protein before introducing 50 μL of anti-6x-His-HRP (diluted 
1:10,000 in PBST + 1% milk) and incubating at room temp with slow mixing for 1 h. Three final 
washes were performed before incubation with 200 μL OPD (Sigma Fast tablets) in the dark for 
30 min. The reaction was then quenched with 50 μL 3N H2SO4 and absorbance read at 492 nm.  
In vitro ubiquitination assay. Ubiquitination assays were performed as previously described 
[48] in the presence of 0.1 μM purified human recombinant UBE1 (Boston Biochem), 2 μM 
human recombinant UbcH5α/UBE2D1 (Boston Biochem), 3 μM uAb (or equivalent control 
protein), 3 μM E. coli β-gal (Sigma), 50 μM human recombinant ubiquitin (Boston Biochem), 4 
mM ATP and 1 mM DTT in 20 mM MOPS, 100 mM KCl, 5 mM MgCl2, pH 7.2. Reactions 
were carried out at 37°C for 2 h (unless otherwise noted) and stopped by boiling in 2x Laemmli 
loading buffer for analysis by immunoblotting. 
Mass spectrometry analysis. For LC-MS/MS sample preparation, ubiquitination assays were 
performed as previously described [54] but with 0.1 μM UBE1, 20 μM UbcH5α, 20 μM R4-
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uAb, 20 μM β-gal and 500 μM ubiquitin. Reactions were resolved by SDS-PAGE and stained by 
Coomassie prior to gel excision. The protein bands were cut from an SDS-PAGE gel and cut into 
~1 mm cubes. The gel bands were washed in 200 µL DI water for 5 min, followed by 200 µL 
100 mM ammonium bicarbonate (ambic)/acetonitrile (ACN) (1:1) for 10 min and finally 200 µL 
ACN for 5 min. The acetonitrile was discarded and the gel bands were dried in a speed-vac for 
10 min. The gel pieces were rehydrated with 70 µL of 10 mM DTT in 100 mM ambic and 
incubated for 1 h at 56°C. The samples were allowed to cool to room temperature, after which 
100 μL of 55 mM iodoacetamide in 100 mM ambic was added and the samples were incubated at 
room temp in the dark for 60 min. Following incubation, the gel slices were again washed as 
described above. The gel slices were dried and rehydrated with 50 µL trypsin at 50 ng/µL in 45 
mM ambic, 10% ACN on ice for 30 min. The gel pieces were covered with an additional 25 µL 
of 45 mM ambic, 10% ACN and incubated at 37°C for 19 h. The digested peptides were 
extracted twice with 70 μl of 50% ACN, 5% formic acid (FA) (vortexed 30 min, sonicated 10 
min) and once with 70 μl of 90% ACN, 5% FA. Extracts from each sample were combined and 
lyophilized.  
The lyophilized in-gel tryptic digest samples were reconstituted in 20 µL of nanopure 
water with 0.5% FA for nanoLC-ESI-MS/MS analysis, which was carried out by a LTQ-Orbitrap 
Velos mass spectrometer (Thermo-Fisher Scientific) equipped with a CorConneX nano ion 
source device (CorSolutions LLC). The Orbitrap was interfaced with a nano HPLC carried out 
by an UltiMate3000 UPLC system (Dionex). The gel extracted peptide samples (2-4 µL) were 
injected onto a PepMap C18 trap column-nano Viper (5 µm, 100 µm × 2cm, Thermo Dionex) at 
20 µL/min flow rate for on-line desalting and then separated on a PepMap C18 RP nano column 
(3 µm, 75 µm x 15 cm, Thermo Dionex) which was installed in the “Plug and Play” device with 
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a 10-µm spray emitter (NewObjective). The peptides were then eluted with a 90 min gradient of 
5% to 38% ACN in 0.1% FA at a flow rate of 300 nL/min. The Orbitrap Velos was operated in 
positive ion mode with nano spray voltage set at 1.5 kV and source temperature at 275°C.  
Internal calibration was performed with the background ion signal at m/z 445.120025 as the lock 
mass. The instrument was operated in parallel data-dependent acquisition (DDA) mode using FT 
mass analyzer for one survey MS scan for precursor ions followed by MS/MS scans on top 7 
highest intensity peaks with multiple charged ions above a threshold ion count of 7500 in both 
LTQ mass analyzer and HCD-based FT mass analyzer at 7,500 resolution. Dynamic exclusion 
parameters were set at repeat count 1 with a 15 sec repeat duration, exclusion list size of 500, 30 
sec exclusion duration, and ±10 ppm exclusion mass width. HCD parameters were set at the 
following values: isolation width 2.0 m/z, normalized collision energy 35%, activation Q at 0.25, 
and activation time 0.1 msec. All data were acquired using Xcalibur 2.1 operation software 
(Thermo-Fisher Scientific).  
All MS and MS/MS raw spectra were processed and searched using Proteome Discoverer 
1.3 (PD1.3, Thermo-Fisher Scientific) against databases downloaded from NCBI-nr database. 
The database search was performed with two-missed cleavage site by trypsin allowed.  The 
peptide tolerance was set to 10 ppm and MS/MS tolerance was set to 0.8 Da for CID and 0.05 Da 
for HCD. A fixed carbamidomethyl modification of cysteine, variable modifications on 
methionine oxidation, and ubiquitin modification of lysine were set. The peptides with low 
confidence score (with Xcorr score <2 for doubly charged ion and <2.7 for triply-charged ion) 
defined by PD1.3 were filtered out and the remaining peptides were considered for the peptide 
identification with possible ubiquitination determinations. All MS/MS spectra for possibly 
identified ubiquitination peptides from initial database searching were manually inspected and 
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validated using both PD1.3 and Xcalibur 2.1 software.  
Cell culture, transfection and lysate preparation. All cell lines were obtained from ATCC and 
cultured in standard medium at 37°C with 5% CO2. HEK293T and COS-7 cells were cultured in 
DMEM with 10% heat inactivated FBS and 1% antibiotic-antimycotic (Cellgro). BHK21 cells 
were cultured in EMEM with 10% heat inactivated FBS and 1% antibiotic-antimycotic (Cellgro). 
Cells were transfected in 6-well plates at 60-80% confluency with jetPRIME® (Polyplus 
Transfection) and at 4 h post-transfection the growth media was refreshed. For HEK293T cells, a 
1:2 DNA to jETPRIME® (w:v) ratio was used for transfection and 2 µg total DNA was 
transfected per well. For BHK21 cells, a 1:3 DNA to jETPRIME® (w:v) ratio was used for 
transfection and 2 µg total DNA was transfected per well. And for COS-7 cells, a 1:3 DNA to 
jETPRIME® (w:v) ratio was used for transfection and 1 µg total DNA was transfected per well. 
In all experiments, empty pcDNA3 plasmid was used to balance transfection levels across 
samples to reach the total DNA level as specified per cell line. 
At 24 h post-transfection, cells were harvested by trypsinization, washed with PBS and 
frozen at -20°C until analyzed by immunoblotting. Thawed cells were lysed in NP40 lysis buffer 
(150 mM NaCl, 1% Nonidet P-40 and 50 mM TrisHCl, pH 7.4) by pipetting and mixing at 4°C 
for 30 min, followed by removal of the insoluble fraction at 18,000xg at 4°C for 20 min. 
Insoluble pellets were then washed with 50mM TrisHCl and 1mM EDTA, pH 8 followed by 
solubilization in an equal volume of 2% SDS in PBS by boiling for 10 min.  Cooled samples 
were centrifuged at room temp for 10 min at 13,200 RPM to remove remaining cellular debris.  
Both soluble and insoluble fractions were boiled in 2x Laemmli sample buffer for analysis by 
immunoblotting. Soluble fraction lysates were normalized using a detergent compatible total 
protein assay (Bio-Rad) and 10 µg total protein was loaded with equivolume insoluble fractions 
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for immunoblotting comparison. 
Protein analysis. SDS-PAGE and immunoblotting of proteins was performed according to 
standard procedures. BioRad Coomassie G-250 stain was used to visualize proteins in SDS-
PAGE (BioRad, Mini-PROTEAN® TGX). The following primary antibodies were utilized for 
immunoblotting: rabbit anti-β-gal (Abcam, ab616), mouse anti-ubiquitin (Millipore, P4D1-A11), 
rabbit anti-Lys48 (Millipore, Apu2), rabbit anti-6x-His-HRP (Abcam, ab1187), mouse anti-
GAPDH (Millipore, 6C5), mouse anti-FLAG®-HRP (Sigma, M2), mouse anti-Hsp70 (Enzo Life 
Sciences, C92F3A).  Secondary antibodies goat anti-rabbit IgG (H+L) and anti-mouse IgG 
(H+L) with HRP conjugation (Promega) were utilized as needed. 
Pull-down assays. Thawed cells were lysed as above; then clarified lysates were normalized by 
a detergent compatible total protein assay (Bio-Rad) and diluted to contain 0.75 mg/mL of 
protein with 10 mM imidazole to reduce non-specific binding. 200 μL of diluted lysates were 
incubated with 30 μL of Ni-NTA magnetic agarose beads (Qiagen, 5% solution) mixing at 4°C 
for 1-2 h and washed with 20 mM imidazole in lysis buffer. Bound proteins were eluted with 250 
mM imidazole (50 mM TrisHCl pH 7.9 and 50 mM NaCl) and boiled in 2x Laemmli sample 
buffer for analysis by immunoblotting. 
β-gal activity assay. β-gal activity was determined using a β-gal assay kit (Invitrogen) according 
to the manufacturer’s instructions for the microtiter plate format. Briefly, cell pellets were 
resuspended in 1x lysis buffer (0.25 M Tris, pH 8.0) and lysed with three freeze-thaw cycles 
before clarification at 18,000xg for 5 min at 4°C. Then  2.5 μL HEK293T lysate or 10 mL COS7 
or BHK21 lysate was added to a well containing 50 μL 1x cleavage buffer (0.1 M sodium 
phosphate, 10 μM KCl, 1 μM MgSO4-7H2O, pH 7) with β-mercaptoethanol and 17 μL ONPG (4 
mg/mL). Reactions proceeded at 37°C for 30 min and were stopped with 125 μL stop buffer (1 
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M sodium carbonate) before measuring absorbance at 420 nm. The amount of ONPG hydrolyzed 
was calculated using the following formula: nmoles ONPG hydrolyzed = (Abs420)(1.92x105 nl) / 
(4500 nl/nmole-cm)(1 cm). Specific activity was determined according to the following formula:  
specific activity = ONPG hydrolyzed/t/mg protein; where t is the reaction time in minutes and 
mg is the amount of total protein assayed. The background activity from untransfected cell 
lysates was subtracted for each sample and specific activities within biological samples were 
normalized to cells transfected with β-gal alone. 
Microscopy and Immunofluorescent labeling. Live cell GFP fluorescence imaging was 
performed with a Zeiss Axiovert A1 with LD Plan-Neofluar 40x (0.6 numerical aperture) 
objective.  For immunofluorescent studies, HEK293T cells were grown on glass coverslips 
coated with poly-L-lysine, fixed with 3.7% formaldehyde, permeabilized by 0.2% Triton X-100 
and blocked in 3% fetal bovine serum.  Primary anti-β-gal antibody (Pierce) incubation was done 
at room temperature for 1 h in a humidity chamber, followed by a 1 h incubation at room 
temperature with Alexa Fluor-labeled secondary antibody (AlexaFluor568 goat anti-rabbit IgG, 
Molecular Probes) at room temperature in the dark.  Coverslips were mounted on VectaShield 
mounting media (H-1000) and imaged with the Zeiss Axiovert A1 and 10x EC Plan-Neofluar 
(0.3 numerical aperture) objective with an AxioCam ICm1 digital camera.   
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CHAPTER 3 
EXPANDING SUBSTRATE SPECIFICITY WITH DESIGNER BINDING PROTEINS 
Introduction 
While antibodies and their fragments have been the workhorse for protein-protein 
interactions in biotechnology applications for years, there are many recent developments toward 
using more of nature’s diverse binding domains for engineering applications.  Two major classes 
of engineered binding proteins include immunoglobulin-like domains (e.g. monobodies and 
lipocalins) and domain repeat scaffolds (e.g. ankyrin and leucine-rich repeats). For example, 
monobodies are based on the human 10th fibronectin type 3 domain (10Fn3) which is structurally 
similar to the β-sandwich structure of the VH domain of an antibody. As such, these domains 
contain three loops, which have been diversified to create libraries [44].  Notably, the 10Fn3 
domain does not require disulfide bonds and is devoid of natural free cysteines, making 
monobodies candidates for both intracellular expression and site specific modification using 
cysteine chemistry. The most developed type of repeat scaffold proteins are the designed ankyrin 
repeat proteins (DARPins).  These utilize varying numbers of internal ankyrin repeats (AR), each 
with six randomized residues, and capped with consensus N- and C-terminal ARs which provide 
stability [39, 40].   
In order to confirm the versatility, modularity and robustness of ubiquibodies, we further 
diversified the substrate binding domains fused to CHIP∆TPR by using various designer binding 
proteins (DBPs).  The major design constraint in selecting DBPs for ubiquibody creation is that 
they must be functional in the reducing environment of the cytoplasm.  Thus to test the 
modularity of our ubiquibody design, we have utilized intrabodies, which are selected for 
intracellular stability, and monobodies and DARPins (designed ankyrin repeat proteins), which 
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naturally do not contain disulfide bonds. 
Results 
Diversification of ubiquibodies with DBPs. Using the modular platform developed for 
ubiquibody expression in E. coli (see Fig. 2.2a), we first cloned a collection of scFvs fused to 
CHIP∆TPR to evaluate intracellular expression.  As was predicted, only scFvs selected for 
intracellular stability were well expressed as ubiquibodies in the cytoplasm of E. coli (Fig. 3.1a).  
Notably, scFvs 3DX and HAG which were isolated by phage display and E. coli periplasmic 
expression respectively did not show soluble expression as fusions to CHIP∆TPR [60, 61]. Yet 
most intrabodies, including scFv13-R4, D10, and J21 created stable, soluble ubiquibodies when 
fused to CHIP∆TPR (Fig. 3.1a).  Both scFv D10 and J21 were selected from a synthetic human 
combinatorial antibody library (HuCAL®) using a protein fragment complementation assay 
(PCA) in the cytoplasm of E. coli [51]. Clone D10 binds the bacteriophage capsid protein D 
(gpD), and J21 binds c-Jun N-terminal kinase 2 (JNK2) [51].  While the scFv GCN4 was 
selected from an intrabody library utilizing yeast two-hybrid display, this ubiquibody produced 
conflicting results of both soluble and insoluble expression (data not shown) [35].  
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Figure 3.1 Soluble expression of diverse uAbs in E. coli. Western blot analysis of cell lysates 
isolated from E. coli strain BL21(DE3) expressing full-length scFv13-R4, CHIP, CHIPΔTPR, 
and various uAb constructs. (a) The scFv-uAbs were comprised of scFvs specific for E. coli β-
gal (scFv13R4-uAb), S. cerevisiae GCN4 (GCN4-uAb), c-myc epitope (3DX-uAb), 
hemagglutinin epitope (Hag-uAb), JNK2 (J21-uAb) and bacteriophage gpD (D10-uAb) 
respectively. (b) Additional DBP-uAbs were comprised of the monobody YS1 and the DARPin 
off7, both specific for E. coli MBP (YS1-uAb and off7-uAb accordingly). An equivalent amount 
of total protein was loaded in each lane and anti-FLAG® antibodies were used to detect the 
expressed proteins.  
 
Next we created ubiquibodies from non-immunoglobulin domains and compared their soluble 
expression in E. coli to intrabody based ubiquibodies (Fig. 3.1b).  Specifically, we tested the 
monobody, YS1 and the DARPin, off7, both of which bind the E. coli maltose binding protein 
(MBP) and found that these smaller DBPs created ubiquibodies as soluble as wild-type CHIP 
(Fig. 3.1b).  Interestingly, YS1, was isolated from a binary library built of tyrosine (Tyr, Y) and 
serine (Ser, S) residues in the binding domain loops, with the aim of studying conformational 
diversity rather than chemical diversity in protein-protein interactions [62, 63].  Alternatively, 
the DARPin utilized in this work, off7, was isolated from a combinatorial library of consensus-
designed ankyrin repeat proteins of varying sizes, using in vitro ribosome display [40].  
Functional testing of scFv-uAbs in vitro.  We next tested the functionality of the most soluble 
scFv-uAbs, D10-uAb and J21-uAb, by purifying the ubiquibodies and their antigens from the E. 
coli strain BL21(DE3). The N-terminus of both antigens (gpD and JNK2) were augmented with 
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a double epitope tag of 6xHis and HA (hemagglutinin) to enable facile purification and 
differentiation from the uAbs by immunoblotting respectively.  Notably neither of these tags 
contains lysine residues.  Then we tested the binding affinity of D10-uAb to gpD and J21-uAb to 
JNK2 by ELISA (Fig. 3.2). The previously characterized R4-uAb, CHIP∆TPR or 5x1-uAb (a 
solubility improved scFv GCN4 uAb) were used as negative controls as they should not interact 
with either antigen.  Interestingly, when the scFv D10 was fused to CHIP∆TPR the binding 
affinity for gpD improved slightly (Fig. 3.2a). CHIP∆TPR alone showed an affinity for gpD that 
was higher than expected, but which was identified to be due to the use of bovine serum albumin 
(BSA) as the blocking agent in the ELISA (compare to CHIP∆TPR signal in Fig. 2.3a, Abs492 < 
0.2). The J21-uAb, however, did not maintain its minimal affinity for JNK2 (Fig. 3.2b). These 
results corroborate independent testing in our laboratory which found J21 to be a weak binding 
scFv which only exhibited differentiable binding affinity from non-binding control scFvs under 
optimized ELISA conditions.  Furthermore, the J21 intrabody was isolated after just one round of 
selection versus the D10 intrabody which was isolated after ten rounds of competitive selection 
[51].  Additionally, the KD for D10 was found to be 30.5 µM as determined by surface plasmon 
resonance (SPR) while the affinity for J21 could not be determined [51].  
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Figure 3.2 In vitro binding activity of scFv-uAbs as determined by ELISA. Binding activity 
of purified D10-uAb with gpD as antigen (a) and purified J21-uAb with JNK2 as antigen (b) as 
measured by ELISA. The D10 and J21 intrabodies served as positive controls while CHIP∆TPR 
and non-specific uAbs served as negative controls. Also tested was D10-uAbI235A, a derivative of 
D10-uAb carrying a point mutation in the U-box domain that is known to block the interaction 
between CHIP and the E2 enzyme, UbcH5α. BSA which does not contain the epitope tag was 
used to show the background signal of the assay.  
 
We next tested the scFv-uAbs for ubiquitin ligase activity by reconstituting the 
ubiquitination process in vitro using human UBE1 for the E1, UbcH5α as the E2 enzyme and 
6xHis-HA-gpD, which has 6 surface lysines [64], or untagged JNK2, which has 20 surface 
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lysines [65], as the substrate proteins.  Monoubiquitination of gpD was clearly evident when 
immunoblots were probed with anti-HA antibodies. Interestingly, the 6xHis-HA-gpD construct 
was not detected by the anti-6xHis antibodies despite analyzing ubiquitination reactions with 
increasing amounts of the substrate protein (Fig. 3.3a).  The J21-uAb showed negligible 
ubiquitination of JNK2, despite using increased amounts of the ubiquibody (Fig. 3.3b). Notably, 
autoubiquitination of both scFv-uAbs was evident, consistent with wild-type CHIP 
autoubiquitination and which indicated that both ubiquibodies were active (Fig. 3.3) [48].  
 
 
Figure 3.3 In vitro ubiquitination activity of scFv-uAbs. In vitro ubiquitination reactions with 
increasing amounts of the substrate protein gpD with the D10-uAb (a) or increasing amounts of 
the J21-uAb with JNK2 (b) were reacted for 2 h at 37°C.  Reactions were stopped by boiling and 
immunoblotted with anti-6xHis, anti-HA and anti-JNK2 antibodies as indicated. Ubiquitination 
assay mixtures boiled prior to incubation were used as controls to identify unmodified proteins (0 
time).  
 
Further testing of D10-uAb with gpD revealed that polyubiquitination could be detected 
with antibodies specific for ubiquitin and K48-linked polyUb chains (Fig. 3.4a), confirming the 
presence of ubiquitin linkages that are known to signal proteasomal degradation [53]. When 
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reactions were performed with scFv D10 or CHIP∆TPR, there was no detectable ubiquitination 
of gpD.  Likewise, D10-uAbI235A, which carries a U-box domain point mutation to interfere with 
E2 binding, showed no modification of gpD, despite binding as well as the wild-type D10-uAb 
(Fig. 3.2a and Fig 3.4a). However, the identity of high molecular weight polyUb proteins was 
convoluted by the extensive autoubiquitination of both D10-uAb and CHIP∆TPR.  Notably, 
neither D10-uAb nor CHIP∆TPR could be detected with anti-FLAG® antibodies (Fig. 3.4a), 
possibly due to ubiquitination of lysine residues within the epitope sequence.  In evaluating the 
ubiquitination activity over time, it was evident that D10-uAb shows slower ubiquitination of 
gpD than wild-type CHIP does ubiquitinating Hsp70 (Fig. 3.4b and c). Finally, in vitro 
ubiquitination of gpD was monitored by SDS-PAGE and the formation of higher molecular 
weight species was used to confirm the presence of gpD-Ubn polyUb chains (Fig. 3.4d) which 
could not be detected directly with anti-HA nor anti-6xHis antibodies (Fig. 3.3a).  Purified 
6xHis-HA-gpD was compared to a complete ubiquitination reaction without incubation (0 time), 
the ubiquitination reaction after 2 h at 37°C, and a ubiquitination reaction lacking gpD, in order 
to account for E2 ubiquitination and uAb autoubiquitination (Fig. 3.4d). Minimally gpD 
modified with three ubiquitins could be detected, confirming polyubiquitination by D10-uAb. 
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Figure 3.4 In vitro ubiquitination of gpD by D10-uAb. (a) Ubiquitination of gpD was carried 
out for 2 h with the controls D10-uAbI235A, scFv D10, and CHIP∆TPR. An equivalent amount of 
total protein was added to each lane. Immunoblots were probed with anti-HA, anti-FLAG®, anti-
K48 linked polyUb and anti-ubiquitin antibodies as indicated. (b & c) At the indicated times, in 
vitro ubiquitination reactions were stopped by boiling and immunoblotted with anti-HA and anti-
Hsp70 antibodies. (d) Purified gpD (only gpD) and ubiquitination reactions at 0 h, 2 h and 2 h 
omitting gpD (no gpD) were analyzed by Coomassie staining. Protein bands corresponding to 
gpD, gpD-Ub conjugates, ubiquitin (Ub), E2, D10-uAb, D10-uAb-Ub conjugates and the 
molecular weight of the marker bands (MW) are indicated. An equivalent amount of total protein 
was loaded in each ubiquitination reaction lane. The purified gpD was loaded equivalent to the 
weight of gpD used in the ubiquitination reactions. 
 
 57 
Ectopic co-expression of gpD with D10-uAb in mammalian cells.  Having determined that 
D10-uAb could bind and ubiquitinate gpD in vitro, we next tested whether co-expression in 
mammalian cells would show targeted degradation of gpD.  HEK293T cells were co-transfected 
with pCMV-HA-gpD, pcDNA3-D10-uAb and pGFP, a plasmid containing the GFP gene to 
evaluate transfection efficiency (Fig. 3.5a). Increasing amounts of D10-uAb appeared to reduce 
the levels of gpD expression while not affecting Hsp70 levels, a native binding partner of CHIP 
(Fig. 3.5a).  Notably, there was no detectable level of D10-uAb expression (using anti-FLAG 
antibodies) without the co-expression of gpD (Fig. 3.5a). This was reproduced with a separate 
co-transfection (data not shown). Unfortunately, the apparent knockdown of gpD in situ was 
unable to be reproduced due to inconsistent expression of HA-gpD. Furthermore, we utilized a 
pull-down assay to test whether gpD was even interacting with D10-uAb in situ (Fig. 3.5b). 
HEK293T cells were transiently transfected with pCMV-HA-gpD alone, or co-transfected with 
pcDNA3-D10-uAb, pcDNA3-scFv D10 or pcDNA3-R4-uAb, which was used as a negative 
control.  Each ubiquibody or scFv contained a C-terminal 6xHis tag which was then used to 
precipitate these proteins using Ni2+ affinity magnetic agarose beads. Unfortunately, neither the 
scFv D10 nor D10-uAb was able to co-precipitate HA-gpD in situ.  These results draw attention 
to the affinity required of ubiquibodies for effective target binding and ubiquitination in the 
eukaryotic cellular context.  
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Figure 3.5 Ectopic co-expression of gpD and D10-uAb in mammalian cells. (a) Immunoblots 
of extracts prepared from HEK293T cells co-transfected with pGFP (transfection control) and 
pCMV-HA-gpD (HA-gpD only) or pcDNA3-D10-uAb (D10-uAb only), or co-transfected with 
all three plasmids. The triangle indicates increasing amounts of pcDNA3-D10-uAb plasmid 
DNA used to co-transfect cells. An equivalent amount of total protein was loaded in each lane 
and blots were probed with antibodies specific for HA, FLAG, Hsp70 and GFP as indicated. (b) 
Immunoblots of pull-down samples or extracts prepared from HEK293T cells transfected with 
pCMV-HA-gpD alone (gpD only) or co-transfected with one of the following: pcDNA3-D10, 
pcDNA3-D10-uAb or pcDNA3-R4-uAb. Pull-down was performed using Ni-NTA magnetic 
agarose beads followed by immunoblotting with antibodies specific for HA, ubiquitin and 6xHis 
as indicated. An equivalent amount of total protein was loaded in each lane, as confirmed by 
immunoblotting with anti-GAPDH antibodies. 
 
Targeting maltose binding protein for degradation with DBP-uAbs. Moving away from the 
scFv-uAbs, we next tested our monobody and DARPin based ubiquibodies which were both 
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specific for the E. coli maltose binding protein (MBP). These uAbs were tested directly in situ by 
co-transfection of HEK293T cells with pcDNA3-MBP and pcDNA3-off7-uAb (Fig. 3.6a) or 
pcDNA3-YS1-uAb (Fig. 3.6b). While the DARPin based off7-uAb did not discernibly reduce 
the levels of MBP expression (Fig 3.6a), increasing amounts of the monobody based YS1-uAb 
systematically reduced MBP levels (Fig.3.6b).  Furthermore, non-specific control ubiquibodies 
D10-uAb and R4-uAb did not affect MBP expression levels (Fig. 3.6).  
 
Figure 3.6 Comparing off7-uAb and YS1-uAb targeted proteolysis of MBP. Immunoblots of 
extracts prepared from HEK293T cells transfected with pcDNA3-MBP alone (MBP only) or co-
transfected with pcDNA3-off7-uAb (a), pcDNA3-YS1-uAb (b), pcDNA3-D10-uAb, or 
pcDNA3-R4-uAb. The triangle indicates increasing amounts of plasmid DNA used to transfect 
cells. An equivalent amount of total protein was loaded in each lane, as confirmed with the 
loading control GAPDH. Blots were probed with antibodies specific for MBP, 6xHis, and 
GAPDH as indicated. 
 
Confirming the YS1-uAb mediated silencing of MBP, replicate co-transfections with 
pcDNA3-MBP and increasing amounts of pcDNA3-YS1-uAb significantly reduced MBP levels 
compared to cells transfected with only the pcDNA3-MBP plasmid (Fig. 3.7a). When HEK293T 
cells were co-transfected with control plasmids expressing YS1 or the non-specific R4-uAb, 
MBP depletion was not observed (Fig. 3.7a and b), confirming that YS1-uAb-mediated 
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proteolysis is CHIP∆TPR-dependent and ubiquibodies are highly specific. Additionally, Hsp70 
levels were unchanged in the presence of YS1-uAb (Fig. 3.7a), demonstrating the remodeled 
specificity of CHIP∆TPR. Finally, in situ binding of MBP by YS1 and YS1-uAb was confirmed 
by co-precipitation (Fig. 3.7b); and the pull-down with YS1-uAb was enriched with 
ubiquitinated proteins.  These results suggest that MBP depletion in mammalian cells results 
from specific target binding and ubiquitination by the engineered YS1-uAb. 
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Figure 3.7 YS1-uAb-mediated proteolysis of MBP in mammalian cells. (a) Immunoblots of 
extracts prepared from HEK293T cells transfected with pcDNA3-MBP alone (MBP only) or co-
transfected with pcDNA3-YS1-uAb, pcDNA3-YS1, or pcDNA3-R4-uAb. The triangle indicates 
increasing amounts of pcDNA3-YS1-uAb plasmid DNA used to transfect cells. An equivalent 
amount of total protein was loaded in each lane. Blots were probed with antibodies specific for 
MBP, 6xHis, Hsp70 and GAPDH as indicated. The immunoblot results are representative of at 
least three replicate experiments. (b) Immunoblots of pull-down samples or extracts prepared 
from HEK293T cells transfected with pcDNA3-MBP alone (MBP only) or co-transfected with 
pcDNA3-YS1, pcDNA3-YS1-uAb or pcDNA3-R4-uAb. Pull-down was performed using Ni-
NTA magnetic agarose beads followed by immunoblotting with antibodies specific for MBP, 
ubiquitin and 6xHis as indicated. An equivalent amount of total protein was loaded in each lane, 
as confirmed by immunoblotting with anti-GAPDH antibodies. 
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Discussion 
Domain swapping with different DBPs (e.g., intrabody and monobody) confirmed the 
conformational flexibility of CHIP in ubiquitin transfer [48], targeting multiple acceptor lysines 
on three structurally distinct substrates. These results also confirm the potential of CHIP for 
customizable target degradation in mammalian cells. Indeed, given the plethora of existing DBPs 
against known cellular targets and the availability of robust technologies for on-demand isolation 
of new DBPs that function inside cells [34, 51, 66], ubiquibodies are likely to become a powerful 
tool for reverse genetics.  
Thus far, we considered the intracellular stability of a DBP as the major design constraint 
in creating ubiquibodies.  However an additional design constraint may be the binding kinetics of 
DBPs. A comparison of the KDs of the DBPs and CHIP with its natural substrates Hsc70, Hsp70 
and Hsp90 is given in Table 3.1. Notably, the two DBPs that showed consistent functionality in 
the eukaryotic cellular context, scFv13-R4 and YS1 have the closest KDs to those reported for 
CHIP.  As well, over-expression of CHIP in situ shows faster degradation of Hsp70 than Hsc70, 
despite their high sequence similarity [67], most likely due to their sequence divergence at the C-
terminus where CHIP binds these chaperones. This is also consistent with their hierarchal 
binding affinities with CHIP when compared under the same experimental set-up (ITC, [68]).  
Table 3.1 Comparison of dissociation constants of CHIP and DBPs.  
Binding 
Protein 
Substrate KD (µM) koff (s-1)/kon (M-1 s-1) Method, Source 
CHIP Hsc70 0.07 (± 0.01) 6x10-3/8.7x104 BLI [69]  
CHIP Hsc70 2.3 (± 0.3) n.d. ITC, [68] 
CHIP Hsp70 0.95 (± 0.01)  n.d. ITC, [68] 
CHIP Hsp90 0.38 (± 0.04) n.d. ITC, [68] 
scFv13-R4 β-gal 0.128 (± 0.049) n.d. Competitive ELISA, [66]  
D10 gpD 30.5 n.d. SPR, [51] 
J21 JNK2 n.d. (50-100) n.d. Estimated, [51] 
YS1 MBP 0.135 7.6x10-2/5.6x105 SPR, [62] 
off7 MBP 0.0044 1.9x10-3/4.2x105 SPR, [40] 
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Also contributing to the significance of binding kinetics, E3 ubiquitin ligases must bind 
both a ubiquitin-charged-E2 and the substrate protein at the same time, creating a ternary 
complex necessary for substrate ubiquitination (Fig. 3.8) [70]. Then, the E3 must stay bound to 
the substrate long enough to enable poly-ubiquitin transfer or risk the substrate being 
deubiquitinated by deubiquitinating enzymes (DUBs) in the cellular milieu [26, 71]. This may 
put significant restraints on suitable koff rates for ubiquibodies because the E2 charged with 
ubiquitin usually must cycle off and be replaced with another charged E2 in order for poly-
ubiquitination to occur [72, 73]. Thus, it will be important that engineered ubiquitin ligases do 
not alter the E2 binding kinetics which defines processive ubiquitin chain synthesis (αKE2~Ub and 
αKE2 in Fig. 3.8) [70, 73].  
 
 
Figure 3.8 Enzyme scheme for ubiquitination kinetics.  The kinetic model is adapted from 
Swinney et al. [70]. KT and αKT are dissociation constants of the ubiquibody for the target, T in 
the absence and presence, respectively, of E2 charged with ubiquitin, E2~Ub, in the U-box 
domain. KE2~Ub and αKE2~Ub are dissociation constants of the ubiquibody for the ubiquitin 
charged E2 in the absence and presence, respectively, of the target in the DBP active site. A 
value of α = 1 indicates that the equilibrium dissociation constants are not influenced by the 
binding of the alternative substrate. KT-Ub and KE2 are dissociation constants of the ubiquibody 
for the ubiquitinated target and E2 without ubiquitin, respectively [70].  
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Materials and Methods 
Plasmid construction. Detailed methodology for the construction of pET28a-CHIP∆TPR, 
pET28a-R4-uAb and pET28a-D10-uAb has been previously described (see Chapter 2 Materials 
and Methods). Separately, each of the DBPs including scFv GCN4 [34], scFv 5x1 (Waraho 
unpublished results), scFv HAG (a gift from Andreas Pluckthun), scFv 3DX (a gift from Bruce 
Mayer), scFv J21 (a gift from Andreas Pluckthun) and DARPin off7 (a gift from Marc 
Ostermeir) were  PCR amplified with a 5’ NcoI site and 3’ EcoRI site and ligated into pET28-
DBP-uAb (Fig. 2.2a). Due to an internal EcoRI site in the monobody YS1 (a gift from Shohei 
Koide), overlap extension PCR was used to add the GSGSG linker and N-terminus of 
CHIP∆TPR to the YS1 PCR product, until reaching a unique BstBI site within CHIP∆TPR. This 
overlap extension PCR product was then ligated between NcoI and BstBI sites of pET28a-R4-
uAb, yielding pET28a-YS1-uAb. The genes encoding scFvs D10 and J21 were also PCR 
amplified with a 5’ NcoI site and 3’ SalI site and ligated into pET28-DBP-uAb carrying the 
double epitope Flag-6xHis tag, yielding the control plasmids pET28a-D10 and pET28a-J21, 
respectively. 
For expression in eukaryotic cells, select constructs were PCR amplified from their 
pET28a(+) backbones using primers that introduced a Kozak sequence at the start codon as well 
as a 5’ HindIII site and a 3’ XbaI site. The resulting PCR products were then cloned between the 
HindIII and XbaI sites of plasmid pcDNA3, yielding pcDNA3-D10, pcDNA3-YS1-uAb and 
pcDNA3-off7-uAb.  Due to an internal SalI site, the YS1 gene was directly cloned into pcDNA3 
for the construction of pcDNA3-YS1 using overlap extension to add a HindIII site and Kozak 
sequence to the 5’ end and FLAG tag, 6x-His tag and XbaI site to the 3’ end. The transformation 
 65 
control plasmid pGFP was a gift from Pengbo Zhou.  
The target substrate gpD (a gift from Andreas Pluckthun) was PCR amplified from using 
primers with a 5’ NdeI site and a 3’ HindIII site. DNA encoding a double tag of 6x-His-HA was 
created by dimerizing primers with a 5' NcoI overhang and a 3’ NdeI overhang. Double ligation 
was performed to insert the gpD PCR product and primer dimer between NcoI and HindIII sites 
in pET28a(+), yielding plasmid pET28a-6xHis-HA-gpD. Using this backbone, the substrate 
JNK2 (a gift from Andreas Pluckthun) was PCR amplified using primers with a 5’ NdeI site and 
a 3’ HindIII site, digested and ligated to create pET28a-6xHis-HA-JNK2. For eukaryotic 
expression, HA-gpD was PCR amplified from the pET28a construct with a 5’ and 3’ NotI site for 
ligation into pCMV. The target substrate protein MBP was PCR amplified using primers that 
introduced a Kozak sequence at the start codon as well as 5’ HindIII and a 3’ XbaI site, and 
cloned in the corresponding sites of pcDNA3.  
Protein expression and purification.  All purified proteins were obtained from cultures of E. 
coli BL21(DE3) cells grown in 50 mL of Luria-Bertani (LB) medium. Expression was induced 
with 1 mM IPTG when the culture density (Abs600) reached 0.6-0.8 and proceeded at 30°C for 6 
h, after which cells were harvested by centrifugation at 4,000xg for 20 min at 4°C. The resulting 
pellets were stored at -20°C overnight.  Thawed pellets were resuspended in 4 mL binding buffer 
(50 mM TrisHCl pH 7.9, 500 mM NaCl, 1% Tween20 and 5 mM imidazole) and lysed by 
sonication (30 sec three times, per 1 mL aliquot).  Lysates were cleared by centrifugation at 
12,000xg for 15 min at 4°C and then subjected to Ni2+-affinity purification with Ni-NTA Spin 
Columns (Qiagen). Samples were washed with the Tris-based buffer with 60 mM imidazole 
before elution in 250mM imidazole buffer lacking 1% Tween20.  
Enzyme-linked immunosorbent assay (ELISA).  For ELISA, a previously established protocol 
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was used to detect binding to gpD and JNK2 [33], with slight modification. Briefly, a 96-well 
EIA plate was coated overnight at 4°C with 100 μL 6x-His-HA-JNK2 at 10 μg/mL in PBS or 
100 μL 6x-His-HA-gpD in coating buffer (0.05 M Na2CO3 pH 9.6). The plate was then washed 
three times with 100 μL PBST (1x PBS + 0.1% Tween20) per well for 5 min with shaking and 
blocked with 100 μL PBS-BSA (1x PBS + 50 µg/mL BSA) per well at room temp, slowly 
mixing for 2 h. Following three washes as above, purified protein samples were introduced in 
blocking buffer as serial dilutions with 40 μL per well and incubated at room temp slowly 
mixing for 1 h. Three washes were used to remove non-bound protein before introducing 50 μL 
of anti-flag-HRP (diluted 1:10,000 in PBS) and incubating at room temp with slow mixing for 1 
h. Three final washes were performed before incubation with 200 μL OPD (Sigma Fast tablets) 
in the dark for 30 min. The reaction was then quenched with 50 μL 3N H2SO4 and absorbance 
read at 492 nm. Notably, the ELISA procedure used here was later improved upon by using milk 
for blocking instead of BSA, which dramatically reduced the binding of negative controls such 
as CHIP∆TPR (see Chapter 2 Materials & Methods). 
In vitro ubiquitination assay. Ubiquitination assays were performed as previously described 
[48] in the presence of 0.1 μM purified human recombinant UBE1 (Boston Biochem), 2 μM 
human recombinant UbcH5α/UBE2D1 (Boston Biochem), 3 μM uAb (or equivalent control 
protein), 3 μM 6xHIS-HA-gpD or 3 μM inactivated JNK2 (Invitrogen), 50 μM human 
recombinant ubiquitin (Boston Biochem), 4 mM ATP and 1 mM DTT in 20 mM MOPS, 100 
mM KCl, 5 mM MgCl2, pH 7.2. Alternatively for Coomassie evaluation, reactions were 
performed as for MS analysis, with 0.1 μM UBE1, 20 μM UbcH5α, 20 μM D10-uAb, 20 μM 
gpD and 500 μM ubiquitin.  Reactions were carried out at 37°C for 2 h (unless otherwise noted) 
and stopped by boiling in 2x Laemmli loading buffer for analysis by immunoblotting. 
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Cell culture and transfection. HEK293T cells were cultured in DMEM with 10% heat 
inactivated FBS and 1% antibiotic-antimycotic (Cellgro) at 37°C with 5% CO2. Cells were 
transfected at 60-80% confluency with jetPRIME® (Polyplus Transfection) using 2 µg total 
DNA per well in a 6-well plate with a 1:2 jetPRIME® ratio and at 4 h post-transfection the 
growth media was refreshed. At 24 h post-transfection, cells were harvested in PBS and frozen at 
-20°C until analyzed by immunoblotting. Thawed cells were lysed in NP40 lysis buffer (150 mM 
NaCl, 1% Nonidet P-40 and 50 mM TrisHCl, pH 7.4) by pipetting and mixing at 4°C for 30 min, 
followed by removal of the insoluble fraction at 18,000xg at 4°C for 20 min. Insoluble pellets 
were then washed with 50mM TrisHCl and 1mM EDTA, pH 8 followed by solubilization in an 
equal volume of 2% SDS in PBS by boiling for 10 min.  Cooled samples were centrifuged at 
room temp for 10 min at 13,200 RPM to remove remaining cellular debris.  Both soluble and 
insoluble fractions were boiled in 2x Laemmli sample buffer for analysis by immunoblotting. 
Soluble fraction lysates were normalized using a detergent compatible total protein assay (Bio-
Rad) and 10 µg total protein was loaded with equivolume insoluble fractions for immunoblotting 
comparison. 
Pull-down assays. Thawed cells were lysed as above; then clarified lysates were normalized by 
a detergent compatible total protein assay (Bio-Rad) and diluted to contain 0.75 mg/mL of 
protein with 10 mM imidazole to reduce non-specific binding. 200 μL of diluted lysates were 
incubated with 30 μL of Ni-NTA magnetic agarose beads (Qiagen, 5% solution) mixing at 4°C 
for 1-2 h and washed with 20 mM imidazole in lysis buffer. Bound proteins were eluted with 250 
mM imidazole (50 mM TrisHCl pH 7.9 and 50 mM NaCl) and boiled in 2x Laemmli sample 
buffer for analysis by immunoblotting. 
Protein analysis. SDS-PAGE and immunoblotting of proteins was performed according to 
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standard procedures. BioRad Coomassie G-250 stain was used to visualize proteins in SDS-
PAGE (BioRad, Mini-PROTEAN® TGX). The following primary antibodies were utilized for 
immunoblotting: rabbit anti-HA (Sigma, H6908), mouse anti-JNK2 (MBLI, 0301), mouse anti-
ubiquitin (Millipore, P4D1-A11), rabbit anti-Lys48 (Millipore, Apu2), rabbit anti-6x-His-HRP 
(Abcam, ab1187), mouse anti-GAPDH (Millipore, 6C5), mouse anti-FLAG®-HRP (Abcam, 
ab49763), mouse anti-Hsp70 (Enzo Life Sciences, C92F3A), mouse anti-GFP (Roche, clones 7.1 
and 13.1), mouse anti-MBP-HRP (NEB, E8038).  Secondary antibodies goat anti-rabbit IgG 
(H+L) and anti-mouse IgG (H+L) with HRP conjugation (Promega) were utilized as needed.  For 
ELISA detection, mouse anti-FLAG®-HRP (Abcam, ab49763) was used. 
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CHAPTER 4 
RATIONAL DESIGN OF UBIQUIBODIES FOR ENHANCED ACTIVITY 
Introduction 
The ubiquitin ligase CHIP (carboxyl terminus of Hsc70-interacting protein) was first 
discovered due to its N-terminal tetratricopeptide repeat (TPR) domain that allows it to bind and 
regulate heat shock proteins (Hsp) which act as chaperones for unfolded or misfolded proteins 
[46].  It was later realized that this 35 kDa cytoplasmic protein also contains a C-terminal U-box 
domain, which binds ubiquitin conjugating enzymes (E2s) and mediates ubiquitin ligase activity 
[74].  The U-box is a 75 amino acid domain first identified in yeast and is considered a non-
canonical RING domain, thus classifying proteins containing it as E3 ubiquitin ligases [75].  In 
combining the functions of the N- and C-terminal domains, CHIP has the ability to assist in both 
chaperone-associated folding and the degradation of chaperone substrates, giving it a unique role 
in protein quality control [74].  Indeed, it has been shown that CHIP contains intrinsic chaperone 
functions in collaboration with Hsp70 and independently [47, 76]. 
 To date, the ubiquitin ligase activity of CHIP has been shown to target a myriad of 
proteins for proteasomal degradation.  These include chaperone-bound substrates (e.g. cystic-
fibrosis transmembrane-conductance regulator [77], glucocorticoid receptor [78], and β-amyloid 
[79]), the chaperones themselves (e.g. Hsc70, Hsp70 and Hsp90 [67]), and directly bound target 
proteins (e.g. apoptosis signal-regulating kinase 1 [80], Runx1 [81], and Smad1 [82]). This 
substrate diversity also reveals CHIP’s functionality in multiple sub-cellular compartments 
including the endoplasmic reticulum, nucleus and cytoplasm [75]. It has been shown that CHIP 
sequentially ubiquitinates chaperone-bound substrates before the chaperone protein itself [67].  
As well, CHIP interacts with a variety of E2s, including the UbcH5 family in the formation of 
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diverse polyubiquitin chains, including Lys48-linked chains, and with the E2 heterodimer 
Ubc13-Uev1a in the formation of Lys63-linked chains [59, 75]. 
Furthermore, the crystal structure of CHIP has been solved in complex with the C-
terminal peptide of Hsp90α , the E2 heterodimer Ubc13-Uev1a and the E2 UbcH5α [45, 50, 59].  
Zhang et al. found that full-length murine CHIP co-crystallized with the human Hsp90α C-
terminal peptide forms an asymmetric homodimer (Fig. 4.1).  The main difference between the 
two protomers of CHIP in the asymmetric homodimer is the intrinsic flexible helical linker (α7) 
which takes on a “straight” (Fig. 4.1a) or “bent” (Fig. 4.1b) conformation. The dimer has 
interfaces of hydrophobic packing between the U-boxes and α-helix 7 (Fig. 4.1c), supporting the 
finding that the flexible helical linker is required for dimerization and functionality [83].   
 
Figure 4.1 Crystal structure of CHIP (taken from Zhang et al, [45]). Secondary structure 
cartoon of the elongated CHIP protomer (a) compared to the bent conformation (b). The protein 
is rainbow colored (blue to red) from the N- to C-terminus, showing the tetratricopeptide repeat 
domain (TPR), helical hairpin linker (HH), and the U-box domain. (c) The asymmetric CHIP 
homodimer, with the co-crystallized Hsp90α C-terminal decapeptide bound to each TPR domain 
shown in magenta. Images were produced by [45] using MacPyMOL. 
 
In studying the asymmetric dimer, they realized that CHIP was only able to bind its E2, in the 
straight conformation because in the bent conformation the U-box is blocked by the TPR domain 
(Fig. 4.1c).  Functionally, this means that only half of the CHIP dimer is available for E2 
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activity, which may help facilitate the formation of uniform polyubiquitin chains (i.e. not mixed 
linkages) [45]. They also found that the U-box domain interacts solely with Ubc13 which then 
recruits and binds Uev1a to form the heterodimeric E2.  Upon co-crystallization of CHIP’s U-
box domain with the E2 UbcH5α, Xu et al. found that both Ubc13 and UbcH5 interface with the 
same surface of the U-box domain of CHIP (Fig. 4.2a (Ubc13) and 4.2b (UbcH5α)).  
 
Figure 4.2 CHIP co-crystal structures with E2s.  Models of CHIP co-crystallized with E2s, 
Ubc13-Uev1a (a, [45]) or UbcH5α (b, [59]). E2s Ubc13-Uev1a and UbcH5α were co-
crystallized with the U-box domain of CHIP, then U-box dimers from the co-crystal structures 
were superimposed on the full-length CHIP dimer crystal structure to create the models (a) and 
(b) respectively. Detailed interactions between the S-P-A motif of Ubc13 (c) and UbcH5α (d) 
and CHIP’s U-box. Likely hydrogen bonds or salt bridges are shown as dotted lines.  Images 
taken from [59] were made in Pymol. 
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Notably, both UbcH5 and Ubc13 E2s have a conserved Ser-Pro-Ala motif in the binding pocket 
which makes a hydrogen bond with the carbonyl group of P269 and has van der Waals 
interactions with H260, V264 and V270 in the U-box domain of CHIP (Fig. 4.2c and 4.2d) [59].  
However, differences in the E2 binding pockets informed mutagenesis studies to determine 
which residues are essential for ubiquitination activity with each E2 [59].   
Clearly, the structural and functional information about CHIP made it an ideal ubiquitin 
ligase to use in ubiquibody development.  Yet there were still features which could potentially be 
improved upon by rational design. Specifically, we hypothesized that we could refine the E2 
specificity of ubiquibodies using the aforementioned mutagenesis studies.  This is important 
because E2s play a significant role in directing the polyUb chain linkage formation which target 
substrates to the proteasome [14].  Secondly, we could use rational design to modulate the 
conformational flexibility of ubiquibodies required for substrate ubiquitination [48]. Finally, we 
sought to reduce the autoubiquitination of ubiquibodies which could increase protein half-life. 
Results 
Refining E2 ubiquitin conjugating enzyme preference. CHIP’s diversity of E2 interactions 
may consequently diversify the polyUb chain formation on target proteins, as E2s often 
determine the polyUb chain linkage [14]. Thus in an attempt to reduce non-proteasomal polyUb 
linkages, we utilized studies by Xu et al. of CHIP:E2 interactions which revealed that the K234A 
point mutant reduced Ubc13-Uev1a interaction, which is known to create K63-linked chains, 
while maintaining UbcH5 binding and activity (Fig. 4.3a) [59]. This point mutation was made in 
R4-uAb and tested for in vitro functionality with UbcH5α and the target β-gal (Fig. 4.3b). While 
ubiquitination of β-gal was still detectable, it was notably reduced compared to wild-type R4-
uAb.  
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Figure 4.3 CHIP point mutants that specify E2 interactions. (a) Taken from Xu et al., in vitro 
ubiquitination assays carried out in ELISA format detecting His-CHIP autoubiquitination with 
UbcH5β or free polyUb chains formed with Ubc13-Uev1a and untagged CHIP [59]. (b) In vitro 
ubiquitination assays carried out for 2 h with the E2, UbcH5α, substrate β-gal and E3s, R4-uAb 
or R4-uAbK234A as indicated. Ubiquitination assay mixtures boiled prior to incubation were used 
as controls to identify unmodified proteins (0 time). An equal amount of total protein was loaded 
per lane and immunoblots were probed with antibodies for β-gal.  
 
We also utilized the U-box point mutations, I235A and R272A, which were identified to 
interfere with UbcH5 binding (Fig. 4.3a). These served as negative controls to show the 
dependence of target ubiquitination on R4-uAb:E2 interactions (Fig. 4.4). Specifically, R4-uAb 
was compared to R4-uAbI235A using in vitro ubiquitination reactions evaluated over time and 
showed no polyUb even after 2 h at 37°C, as evaluated with antibodies detecting both β-gal and 
ubiquitin (Fig. 4.4a). Similarly, R4-uAbR272A was tested for ubiquitination of β-gal compared to 
wild-type R4-uAb and the controls scFv13-R4, CHIP∆TPR, and the non-specific D10-uAb (Fig. 
4.4b). This confirmed the requirement for both E2 and substrate interaction with the uAb for 
targeted ubiquitination to proceed.  While previous works utilized H260Q or P269A as CHIP U-
box point mutants to disrupt E2 binding, we found that both point mutations significantly 
reduced R4-uAb expression in E. coli and therefore results were inconclusive in purified in vitro 
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ubiquitination assays (data not shown) [4, 67].   
 
Figure 4.4 U-box point mutants for inhibiting E2 interactions. In vitro ubiquitination of β-gal 
was carried out with R4-uAb, R4-uAbI235A (a), scFv13-R4, CHIP∆TPR, D10-uAb, or R4-
uAbR272A (b) as E3s. An equivalent amount of total protein was added to each lane. Immunoblots 
were probed with anti-β-gal and anti-ubiquitin antibodies. Molecular weights of the marker 
bands (MW) are indicated.  
 
All R4-uAb point mutants known to interfere with E2 interactions were next tested in HEK293T 
cells to determine if E2 inhibition would reduce or eliminate β-gal knockdown (Fig. 4.5).  On 
two separate occasions, none of the R4-uAb U-box mutants reduced β-gal knockdown as would 
be predicted.  In fact, many of the point mutations appeared to knockdown β-gal levels as well 
as, or better than wild-type R4-uAb (Fig. 4.5 and data not shown).  It was also evident that all U-
box mutant ubiquibodies had reduced expression in HEK293T (Fig. 4.5).  However, both 
replicates of testing U-box point mutants were performed with the high level of pcDNA3-β-gal 
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transfection where knockdown was convoluted by sequestration to the insoluble fraction (see 
Fig. 2.11 and Fig. 2.12). As noted in chapter 2, the reduced levels of β-gal expression seen could 
be largely due to sub-cellular partitioning, rather than proteasomal degradation. Interestingly, 
CHIPH260Q has previously been shown to preferentially sequester a natural substrate, iNOS 
(inducible nitric oxide synthase), to a detergent-resistant fraction [84]. This suggests that the U-
box activity mutants may show an enhanced loss of soluble β-gal compared to wild-type R4-uAb 
by sequestering more β-gal into the detergent-resistant fraction rather than having more efficient 
UPP degradation.  In fact, preliminary proof was shown in Figure 2.13 where HEK293T cells 
were co-transfected with ten-fold less pcDNA3-β-gal and R4-uAbR272A, yet the insoluble fraction 
of cells still revealed a small amount of β-gal.  Thus, further characterization of point mutants 
which interfere with E2 binding will need to be made in eukaryotic cells to determine the nature 
of β-gal knockdown detected. Minimally, ubiquibody point mutants should be re-tested at the 
lower β-gal transfection level used to validate proteasomal knockdown in chapter 2. Further 
studies could be an alternative future direction for ubiquibody research and will be elaborated 
upon in chapter 5. 
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Figure 4.5 Ubiquibody U-box mutants in HEK293T cells.  Immunoblots of soluble extracts 
prepared from HEK293T cells transfected with 0.5 µg pcDNA3-β-gal alone (β-gal only) or co-
transfected with pcDNA3-R4-uAb, pcDNA3-R4-uAbmutant, or pcDNA3-D10-uAb. An equivalent 
amount of total protein was loaded in each lane. Blots were probed with antibodies specific for 
β-gal, 6xHis, GAPDH and Hsp70 as indicated. 
  
Enhancing ubiquitin ligase flexibility. Ubiquitin ligase flexibility is necessary for substrate 
ubiquitination due to the ‘macromolecular juggling’ required amidst E2 and substrate 
interactions [85]. In CHIP, the α-helical domain, between the two binding domains, is required 
to maintain conformational flexibility for active ubiquitination [48].  Our early tests of solubility 
in E. coli revealed that the addition of a short Gly-Ser-Gly-Ser-Gly (GSGSG) linker significantly 
improved ubiquibody expression (Fig. 4.6a).  Thus as we began testing intrabodies with reduced 
stability (e.g. scFvs 5x1, C4 and NAC32), we introduced longer linkers to determine if these 
could further improve uAb expression (Fig. 4.6b). Specifically we tested the flexible Gly-Ser 
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linkers commonly found in scFvs, (Gly4Ser)3 and (Gly4Ser)5. The only discernible improvement 
of solubility was with NAC32-uAb which was found to be significantly degraded, but in which 
longer linkers did increase overall expression (Fig. 4.6b).  Additionally, we tested purified D10-
uAbs with the longer linkers for in vitro ubiquitination, where previously we’d only been able to 
detect monoubiquitination of the small substrate, gpD by immunoblotting.  We hypothesized that 
polyUb of gpD could be enhanced with greater uAb flexibility (Fig. 4.6c). However, no 
improvement of gpD ubiquitination was detectable by immunoblotting.  
While general improvements of stability or ubiquitination activity were not evident with 
in vitro ubiquitination reactions, longer linkers may prove especially valuable with the continued 
use of smaller format DBPs. From the asymmetric CHIP dimer crystal structure, the TPR domain 
effectively blocks the U-box domain from E2 binding in the bent conformation, which may 
prove significant in the ubiquitination of substrates [48]. Additionally, it’s been shown that the 
natural helical linker in CHIP is necessary for dimerization and ubiquitination activity [83], so an 
additional flexible linker may be helpful in accommodating non-natural DBPs while maintaining 
the dimer interface.  Alternatively, too much flexibility may hinder essential substrate:uAb:E2 
interactions, (e.g. U-box domain blocking) required for E2 cycling and polyUb chain formation. 
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Figure 4.6 Ubiquibody linkers for enhanced flexibility. Western blot analysis of cell lysates 
derived from E. coli strain BL21(DE3) comparing the expression of ubiquibodies with (a) 
scFv13-R4 fused to CHIP∆TPR with and without the GSGSG linker, and (b) scFv13-R4, D10, 
scFv5x1, C4, and NAC32 with GSGSG, (G4S)3 or (G4S)5 linkers. Lysates were normalized by 
total protein and immunoblots probed with anti-FLAG® antibodies. (c) In vitro ubiquitination of 
gpD was carried out for 2 h with D10-uAbs with the linkers GSGSG, (G4S)3 or (G4S)5. A 
ubiquitination assay mixture with the D10-uAb (GSGSG) was boiled prior to incubation as a 
control to identify unmodified proteins (0 time). An equivalent amount of total protein was 
added to each lane and immunoblots were probed with anti-HA and anti-K48 linked polyUb 
antibodies as indicated.  
 
Reducing autoubiquitination of ubiquibodies. Another design aspect worth considering is the 
known autoubiquitination of CHIP [48], which could diminish protein half-life. However, even 
though polyubiquitination of ubiquibodies was consistently observed in vitro (Fig. 4.7a), stable 
accumulation of ubiquibodies was observed in mammalian cells, with expression levels 
increasing in a plasmid dose-dependent fashion (see Fig. 2.13 and 3.7). Nonetheless, it might be 
possible to eliminate autoubiquitination by mutating acceptor lysines in CHIP∆TPR without 
adversely affecting the ubiquibodies’ solubility, protein-protein interactions or catalytic activity. 
Notably, it has been shown that the RING E3, Mdm2 promotes autoubiquitination via 
ubiquitination of a specific lysine residue, in contrast to most site specificity studies which have 
revealed a lack of lysine specificity [26].  Thus, we sought to determine if any single lysine 
residue within CHIP∆TPR could be attributed site specific autoubiquitination. We choose only to 
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look at lysine residues within CHIP∆TPR with the desire to avoid adding an additional design 
constraint to DBPs and to avoid interfering with substrate recognition. We began by performing 
an alanine screen in R4-uAb of each lysine residue in the CHIP∆TPR domain, of which there are 
eleven.  Each point mutant was then expressed in the E. coli strain BL21(DE3) (Fig. 4.7b), 
purified and tested for the ability to ubiquitinate the target β-gal and autoubiquitinate (Fig. 4.7c).  
Remarkably, one clone, R4-uAbK287A showed decreased autoubiquitination.   
 
Figure 4.7 Alanine screening of lysine residues in CHIP∆TPR.  (a) In vitro ubiquitination 
assays with gpD as the target protein and D10-uAb or R4-uAb as the E3s.  Autoubiquitination 
was evident in laddering to higher molecular weight species as detected with anti-FLAG® 
antibodies. (b) Western blot analysis of cell lysates derived from E. coli strain BL21(DE3) 
expressing R4-uAb with Lys to Ala mutations made as noted. An equivalent amount of total 
protein was loaded in each lane and anti-6xHis antibodies were used to detect the expressed 
proteins. The structural domains in CHIP∆TPR of the mutations are annotated below. (c) In vitro 
ubiquitination assays with Lys to Ala R4-uAb mutants from (b) after purification using Ni2+ 
chromatography.  Assays included β-gal as the substrate protein and used UbcH5α as the E2. An 
equivalent amount of protein was loaded per lane and immunoblots were probed with anti-6xHis 
and anti-β-gal antibodies as indicated. 
 
Next the R4-uAbK287A mutant was tested in HEK293T cells to determine if reduced 
autoubiquitination would improve upon wild-type R4-uAb knockdown of β-gal (Fig. 4.8a and 
b).  Preliminary studies showed that R4-uAbK287A was expressed at a lower level in HEK293T 
cells than wild-type and thus the more conservative K287R mutation was also made and found to 
recover some of the uAb expression (Fig. 4.8a). Unfortunately both reduced solubility (due to 
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misfolding) and autoubiquitination would lead to proteasomal degradation of the ubiquibody, 
making decoupling these two outcomes difficult. Furthermore, both R4-uAbK287A and R4-
uAbK287R gave mixed results with regards to β-gal silencing in HEK293T cells (Fig. 4.8a and b) 
Thus, preliminary studies towards reducing autoubiquitination of uAbs by single lysine 
mutations proved inconclusive in the presence of the natural ubiquitin proteasome pathway. 
  
Figure 4.8 Evaluating uAb autoubiquitination in HEK293T cells. (a) Immunoblots of soluble 
extracts prepared from HEK293T cells transfected with 0.5 µg pcDNA3-β-gal alone (β-gal only) 
or co-transfected with pcDNA3-R4-uAb, pcDNA3-R4-uAbK287A, pcDNA3-R4-uAbK287R, or 
pcDNA3-D10-uAb. An equivalent amount of total protein was loaded in each lane. Blots were 
probed with antibodies specific for β-gal, 6x-His, GAPDH and Hsp70 as indicated. (b) Replicate 
experiment of (a).  
 
Discussion 
At this point, preliminary tests have been performed with engineered ubiquibodies 
towards specifying E2 interactions, improving flexibility and reducing autoubiquitination.  
Further testing of the U-box K234A mutant, which reduces interactions with Ubc13, could prove 
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valuable in deciphering specifically how β-gal knockdown is occurring (i.e. K63-linked versus 
K48-linked polyUb chains).  Similarly U-box activity point mutants H260Q, P269A, I235A and 
R272A in R4-uAb should be tested at lower β-gal transfection levels with insoluble fraction 
evaluation, to determine if detergent-resistant partitioning is common amongst all mutants.  
Notably, when full-length CHIP targets endogenous substrates to the detergent-resistant fraction, 
it requires interactions with heat shock proteins [84].  However, the partitioning seen with 
ubiquibodies may be due to the formation of K63-linked chains which can be recognized by 
HDAC6 and sent to the juxtanuclear aggresome [19].  Thus, it would be informative to perform a 
pull-down with 6xHis-tagged ubiquibodies in mammalian cells to determine what endogenous 
proteins may be interacting with the ubiquibodies (i.e. utilizing antibodies against Hsp70 and 
endogenous CHIP).   
With regards to autoubiquitination, a more careful analysis of protein half-life could be 
performed using the ribosomal inhibitor cycloheximide.  This could elucidate if point mutations 
actually reduce autoubiquitination and degradation in mammalian cell lines. However, as 
previously mentioned, decoupling degradation due to misfolding versus autoubiquitination may 
prove more difficult.  Finally, continued rational design of ubiquibodies would be greatly aided 
by the crystal structure of uAbs, and the co-crystal structures of uAb:E2 and uAb:substrate 
interactions. If ubiquibodies dimerize with straight and bent conformations, it may be necessary 
for DBPs to similarly block the U-box domain in the bent conformation.  As such, this could put 
a size limit on DBPs and would require the substrate to be able to bind the uAb in the bent 
conformation. Thus, a crystal structure could inform the utility of flexible linkers and would 
confirm whether ubiquibodies function similar to wild-type CHIP in an asymmetric homodimer 
conformation.  
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Materials and Methods 
Plasmid construction. Site directed mutagenesis to create all point mutations in pET28a(+)-R4-
uAb was performed using QuikChange II (Stratagene) techniques with modifications.  Briefly, 
primers were designed to be ~30 base pairs with the desired mutation in the middle of the primer, 
a Tm ≥ 78°C, a GC content greater than 40%, and terminating in one or more G or C.  Tm was 
calculated using the following formula: Tm = 81.5 + 0.41(% GC) - (675/N) - % mismatch, where 
N is the primer length in bases and % GC (% guanidine and cytosine content) and % mismatch 
are whole numbers.  PCR reactions were set-up with 50 ng of each primer, 5-20 ng of template 
DNA, 0.2 mM each dNTP, 0.5 µL Phusion HF (2 U/µL), 4 µL 5xGC buffer and water to a final 
20 µL volume.  PCRs were performed using touchdown annealing temperatures from 70°C to 
55°C and extension at 7 °C giving Phusion HF 30 sec per kilobase of plasmid.  PCRs were then 
digested with 1 µL of DpnI restriction enzyme (20 U/µL) at 37°C for 1 h.  Reactions were then 
desalted for 20 min and 5 µL transformed into electrocompetant DH5α E. coli. After recovery, 
cells were grown overnight on solid growth media containing kanamycin, single colonies were 
isolated and plasmid DNA was sent to sequencing to confirm single point mutations. 
 To create longer linkers in pET28a-uAb, the forward primers listed in Table 4.1 were 
used in nested PCRs to extend the 5’ end of CHIP∆TPR to add the appropriate sequences, 
(Gly4Ser)3 or (Gly4Ser)5 respectively with a 5’ terminal EcoRI site for cloning back into pET28a-
uAb.  The reverse primer was used to amplify the 3’ end of CHIP∆TPR and includes the 3’ SalI 
site prior to the double epitope tags in pET28a-uAb (see Fig. 2.2a). 
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Table 4.1 Primers used to create (Gly4Ser)n linkers 
Primer Name Sequence Tm (°C) 
(Gly4Ser)n innermost primer fwd ggt gga ggc agc ggt ggc gga ggc tca gga ggc ggt 
ggc tcccggctgaacttcggggac 
58.7 
(Gly4Ser)5 outer primer fwd ct cag GAATTC ggt gga ggt ggc agt ggc gga ggt 
ggc tct ggc ggt gga ggc agc ggt g 
59.6 
(Gly4Ser)3 outer primer fwd cat cag GAATTC ggc ggt gga ggc agc ggt g 59.6 
SalI-hCHIPdTPR-rev  ctg atg GTC GAC gta atc ctc cac cca gcc att c 59 
 
Additional intracellular scFvs including scFv 6E [86], scFv C4 [87], and scFv NAC32 [88] were 
synthesized by GenScript based on NCBI sequences with a 5’ NcoI site and 3’ EcoRI site in 
pUC57 plasmids.  These were then digested and ligated into pET28-DBP-uAb (Fig. 2.2a).  For 
expression in eukaryotic cells, select constructs were PCR amplified from their pET28a(+) 
backbones using primers that introduced a Kozak sequence at the start codon as well as a 5’ 
HindIII site and a 3’ XbaI site. The resulting PCR products were then cloned between the HindIII 
and XbaI sites of plasmid pcDNA3. 
Protein expression and purification. Purified proteins were obtained from cultures of E. coli 
BL21(DE3) cells grown in 50 mL of Luria-Bertani (LB) medium. Expression was induced with 
0.1 mM IPTG when the culture density (Abs600) reached 0.6-0.8 and proceeded at 30°C for 6 h, 
after which cells were harvested by centrifugation at 4,000xg for 20 min at 4°C. The resulting 
pellets were stored at -20°C overnight.  Thawed pellets were resuspended in 3 mL binding buffer 
(50 mM TrisHCl pH 7.9, 500 mM NaCl, 1% Tween20 and 20 mM imidazole) and lysed by 
sonication (30 sec three times, per 1 mL aliquot).  Lysates were cleared by centrifugation at 
12,000xg for 15 min at 4°C and then subjected to Ni2+-affinity purification with Ni-NTA Spin 
Columns (Qiagen). Samples were washed with the Tris-based buffer with 60 mM imidazole 
before elution in 250 mM imidazole buffer lacking 1% Tween20.  
In vitro ubiquitination assay. Ubiquitination assays were performed as previously described 
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[48] in the presence of 0.1 μM purified human recombinant UBE1 (Boston Biochem), 2 μM 
human recombinant UbcH5α/UBE2D1 (Boston Biochem), 3 μM uAb (or equivalent control 
protein), 3 μM E. coli β-gal (Sigma) or 3 μM 6xHIS-HA-gpD, 50 μM human recombinant 
ubiquitin (Boston Biochem), 4 mM ATP and 1 mM DTT in 20 mM MOPS, 100 mM KCl, 5 mM 
MgCl2, pH 7.2. Reactions were carried out at 37°C for 2 h (unless otherwise noted) and stopped 
by boiling in 2x Laemmli loading buffer for analysis by immunoblotting. 
Cell culture and transfection. HEK293T cells were cultured in DMEM with 10% heat 
inactivated FBS and 1% antibiotic-antimycotic (Cellgro) at 37°C with 5% CO2. Cells were 
transfected at 60-80% confluency with jetPRIME® (Polyplus Transfection) using 2 µg total 
DNA per well in a 6-well plate with a 1:2 jetPRIME® ratio and at 4 h post-transfection the 
growth media was refreshed. At 24 h post-transfection, cells were harvested in PBS and frozen at 
-20°C until analyzed by immunoblotting. Thawed cells were lysed in NP40 lysis buffer (150 mM 
NaCl, 1% Nonidet P-40 and 50 mM TrisHCl, pH 7.4) by pipetting and mixing at 4°C for 30 min, 
followed by removal of the insoluble fraction at 18,000xg at 4°C for 20 min. Soluble fraction 
lysates were normalized using a detergent compatible total protein assay (Bio-Rad), boiled in 2x 
Laemmli sample buffer, and 10 µg total protein was loaded on SDS-PAGE for immunoblotting. 
Protein analysis. SDS-PAGE and immunoblotting of proteins was performed according to 
standard procedures. BioRad Coomassie G-250 stain was used to visualize proteins in SDS-
PAGE (BioRad, Mini-PROTEAN® TGX). The following primary antibodies were utilized for 
immunoblotting: rabbit anti-β-gal (Abcam, ab616), mouse anti-ubiquitin (Millipore, P4D1-A11), 
rabbit anti-Lys48 (Millipore, Apu2), rabbit anti-6x-His-HRP (Abcam, ab1187), mouse anti-
GAPDH (Millipore, 6C5), mouse anti-FLAG®-HRP (Sigma, M2), mouse anti-Hsp70 (Enzo Life 
Sciences, C92F3A), rabbit anti-HA (Sigma, H6908).  Secondary antibodies goat anti-rabbit IgG 
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(H+L) and anti-mouse IgG (H+L) with HRP conjugation (Promega) were utilized as needed.  
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CHAPTER 5 
FUTURE DIRECTIONS OF UBIQUIBODY TECHNOLOGY 
Introduction 
Ubiquitination signaling has diverse roles in maintaining cellular homeostasis.  Its 
activity varies from cellular defense against bacteria [89], to regulating endocytosis, mitosis and 
inflammatory responses, to aiding in DNA damage repair and targeting misfolded proteins for 
degradation [16].  Not unsurprisingly, this complex ubiquitin code is still not fully understood. 
However, as we seek to harness the ubiquitin proteasome pathway, it is clear that we must be 
aware of the possibility for crosstalk amongst ubiquitin signaling pathways.  With this natural 
complexity also comes the opportunity to utilize not only the proteasomal degradation pathway, 
but also alternative pathways of degradation mediated by ubiquitination. In this work, we have 
focused on harnessing the ubiquitin proteasome pathway by means of engineering the E3 
ubiquitin ligase CHIP.  In the future, by considering all the natural degradation pathways we may 
be able to develop a suite of tools for ubiquitination engineering (i.e. proteasomal and 
autophagic) which could have more widespread applicability.  Notably, by working with the 
ubiquitin ligase CHIP, which naturally interacts with various degradation pathways, we are 
uniquely poised to diversify our targeted substrate degradation.  
Endogenous CHIP is known to interact with heat shock proteins in a concerted effort to 
prevent misfolded protein aggregation [76].  In a very elegant way, CHIP is able to aid Hsp70 
substrates in refolding or target them for degradation by the ubiquitin proteasome pathway, then 
CHIP can ubiquitinate the co-chaperone Hsp70 to return the cell to an “unstressed” state [67]. 
However, it has also been shown that CHIP/Hsp70 substrates can be targeted to juxtanuclear 
aggresomes, considered a “second line defense”, when the intracellular degradation capacity is 
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exceeded [90]. Interestingly, substrates can be directed to aggresomes by ubiquitin dependent 
processes (utilizing HDAC6 transport or p62 recognition [58]) or by a ubiquitin independent 
process (utilizing Hsp70/BAG3 transport [91]).  Juxtanuclear aggresomes typically then become 
autophagosomes and sequentially autolysosomes whereby the substrates are degraded.  However 
the precision of this process is not fully known, as it appears that protein content within the 
aggresome may affect the efficiency of autophagy and degradation [92]. Notably, CHIP 
interfaces with both ubiquitin dependent and ubiquitin independent targeting to aggresomes and 
thus ubiquibodies could harness this robust interface for multifaceted targeted protein 
degradation (Fig. 5.1). 
 
Figure 5.1 Endogenous protein degradation routes mediated by CHIP. As illustrated, CHIP 
naturally aids in the balance of protein folding, aggregation, ubiquitination and degradation in 
concert with heat shock proteins and co-chaperones such as BAG. Additionally, misfolded 
proteins can be degraded by the proteasome or autophagy, in ubiquitin dependent or independent 
pathways. Illustration was adapted from Kraft et al. [58]. 
 
Discussion 
One major unanswered question is how are ubiquibodies interfacing with CHIP’s natural 
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signaling pathways? While we removed the TPR domain from CHIP to redirect ubiquibodies, the 
CHIP homodimer crystal structure reveals that the U-box and helical linker are the dominant 
dimerization interactions.  Thus it is feasible that when uAbs are put into the eukaryotic cellular 
context they are also forming heterodimers with endogenous wild-type CHIP.  As such, this 
would enable uAbs to tap into CHIP’s diverse means of targeting substrates for degradation in 
concert with heat shock proteins. In order to further elucidate how ubiquibodies are functioning 
in mammalian cells, a pull-down assay could be used to determine interacting proteins such as 
wild-type CHIP, Hsp70, and the various E2s. 
Possibilities in ubiquibody targeting for autophagic degradation. In light of CHIP’s role in 
the creation of juxtanuclear aggresomes, it is feasible that the detergent-resistant sequestration of 
β-gal by R4-uAb (see Fig. 2.11) was preliminary evidence of ubiquibodies also functioning 
within the autophagy pathway. Additionally, less β-gal was seen in the insoluble fraction 10 h 
post-transfection than at 24 h post-transfection using an intermediate level of β-gal transfection 
(0.1 µg pcDNA3-b-gal, data not shown), which could corroborate the sequential targeting of 
substrates to the proteasome before autophagic degradation [90]. Notably, we never detected the 
presence of MBP in the detergent resistant fraction.  This could reveal the natural preference for 
ubiquibodies to target substrate proteins to the proteasome for degradation.  However, β-
galactosidase forms a tetramer which could, at high expression levels, mimic an aggregation 
prone protein or overwhelm the proteasomal degradation pathway, thus leading to the second 
line of defense, autophagy degradation. While we have suggestive evidence towards 
ubiquibodies functioning within the autophagic pathway, to further study this possibility, 
immunofluorescent co-localization studies could be performed to label with antibodies against 
LC3 an autophagosome marker, or vimentin, which shows the intermediate filament cage around 
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aggresomes [91].  Additionally, it has been shown that the dominant negative point mutant 
CHIPH260Q, primarily sends substrates to the aggresome for degradation [90]. This concept could 
be expanded upon to create dominant negative ubiquibodies that target substrates resistant to 
proteasomal degradation due to aggregation propensity [93] or lack of an unstructured handle 
[94] towards autophagosomes. However, targeting substrates to aggresomes must be cautiously 
undertaken because cytotoxicity would be a possible undesirable byproduct. 
Investigating alternative E3s for targeted degradation. While it could prove powerful to tap 
into the concerted effort of proteasomal and autophagic degradation pathways, it may also 
become unnecessarily complicated.  An alternative approach would be to utilize E3s with more 
specialized functions compared to CHIP’s natural flexibility in concert with chaperones. One 
group of E3s to explore would be the HECT (Homologous to E6AP C-terminus) domain 
containing E3s which contain their own catalytic cysteine which is charged with ubiquitin prior 
to substrate ubiquitination [16]. The direct transfer of ubiquitin to substrate proteins by HECT 
E3s suggests they more directly control the polyubiquitin chain linkages built on substrates.  
Thus by engineering a HECT E3, we could more directly control the substrate polyubiquitination 
and degradation.  To date, the HECT domain of E6AP has been used for ubiquitin ligase 
engineering [7, 95]. Unfortunately the HECT domain alone is about 39 kDa and HECT E3s 
range from 100 kDa to greater than 500 kDa in size [96], which may make them more difficult 
for engineering and analysis by in vitro assays. However, the crystal structures of various HECT 
domains are available and recent studies have revealed a possible mechanism for HECT 
substrate ubiquitination, which would aid in ubiquibody design [97-99].  
Another alternative would be to utilize bacterial E3s with natural specificity for targeting 
substrates for proteasomal degradation.  While prokaryotes do not utilize ubiquitin signaling 
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pathways as eukaryotes do, pathogenic bacteria have evolved to hijack host ubiquitination 
machinery for their own benefit.  These bacteria deliver effector proteins, also known as 
virulence factors, into host cells in order to alter the physiological response of the host [100]. A 
number of these effector proteins have been identified as E3 ubiquitin ligases, with similarities to 
RING or HECT type E3s. Additionally, a new class of ubiquitin ligases has been identified 
within bacterial effector proteins, termed NEL for Novel E3 Ligase [101]. Remarkably, these 
NEL E3s appear to use N-terminal leucine rich repeat (LRR) domains for target binding and 
have novel C-terminal ubiquitin ligase activity domains with a conserved active site cysteine 
[102]. Thus, NEL E3s could be a natural scaffold for utilizing LRR designer binding proteins 
[42] in targeting diverse substrates for proteolytic degradation.  
Controlling ubiquibody activity in space and time. Another future direction for ubiquibodies, 
would be the development of allosteric ubiquibodies with more tightly controlled activity. 
Specifically, coupling ubiquibody activity to a small molecule ligand or light inducibility would 
enable temporal or spatial ubiquibody control. Precedence for small molecule induced E3s is 
present in nature [103] and in previous work studying the flexibility between CHIP’s TPR and 
U-box domains [48]. Additionally, plants utilize light reactive E3s to regulate their circadian 
clock and photoperiodic flowering [104]. Such allosteric ubiquibodies could promote faster 
degradation because their response would only require changes in proteins already present in the 
cell and would not be slowed by having to wait for transcription/translation. As such, these 
ubiquibody “switches” could be very powerful in synthetic biology networks. 
Targeting post-translational modifications. Finally, because ubiquibodies operate at the post-
translational level, the ubiquibody technique has the potential for depleting certain protein 
isoforms while sparing others. Supporting this idea is the finding that natural E3s recognize 
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specifically phosphorylated proteins in cell cycle regulation, thus coupling proteolysis to cyclin-
dependent kinases [26]. Additionally, N-linked high-mannose oligosaccharides are an 
endogenous signal for endoplasmic reticulum associated degradation E3s [105].  In fact, many 
post-translational modifications (PTMs) regulate substrate recognition by E3s, including 
hydroxylation, deacetylation and oxidation [106]. Amazingly, the natural diversity of E3 
ubiquitin ligases has reminded us that “if you can think of it, nature has already tried it a long 
time ago” [42].  Thus it should be natural to extend ubiquibody application towards studying 
post-translationally modified proteins.  Specifically, DBP domains which can selectively bind 
isoforms or PTMs could be employed to degrade and further elucidate distinct functions [107, 
108]. This is significant because isoform targeting is difficult, and PTM-specific silencing is not 
possible using current knockdown methods that function at the level of DNA or RNA. 
Conclusions 
In this work, we have presented a generalizable approach for protein knockdown by 
developing ubiquibodies, which combine the activity of an E3 ubiquitin ligase with the 
specificity of designer binding proteins.  While the ubiquibodies developed to date show the 
potential diversity and robustness of targeted protein degradation, they also reveal potential areas 
for improvement (e.g. binding kinetics and E2 specificity).  However future endeavors may be 
far more ambitious than continuing to optimize CHIP based ubiquibody design and could 
venture into alternative E3 scaffolds, allosteric ubiquibodies or targeting post-translational 
modifications. With such endeavors, the utility of ubiquibodies could be expanded towards 
studying natural protein signaling pathways dependent on temporal or post-translational 
regulations.  As such, the ubiquibody technology has the potential to enable the further dissection 
of protein functions or be used to selectively degrade proteins that underlie human disease.   
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CHAPTER 6 
GK12: FORENSIC DNA FINGERPRINTING 
Introduction 
Cornell’s Learning Initiative in Medicine and Bioengineering (CLIMB) is an NSF funded 
graduate program for kindergarten through 12th grade education (GK-12) based out of the 
Department of Biomedical Engineering. The goal of CLIMB is for graduate students to partner 
with a middle or high school teacher and develop inquiry based curriculum to engage students in 
science, technology, engineering and math (STEM). For my GK-12 experience, I was partnered 
with David Syracuse of Groton High School.  Over a six-week summer program, Dave and I 
participated in GK-12 courses focused on inquiry based learning and curriculum development. 
During this time, Dave also joined me in the DeLisa research labs to learn about and participate 
in my thesis research.  While engaging in research together, we sought to identify areas where 
my research and his classroom curriculum would intersect.  During the 2009-2010 academic 
year, Dave taught Living Environment, NY state’s required basic biology course, in addition to 
two senior level courses, Forensic Science and Environmental Science. I had weekly interactions 
in each of these classrooms, implemented a citizen science program with the Environmental 
Science course, and designed and implemented a Forensic DNA Fingerprinting curriculum.   
Weekly interactions as the “scientist in residence” 
Throughout the academic year I visited Dave’s classes on a weekly basis, either 
expanding on the subject matter with mini-lectures or aiding in classroom laboratory 
experiments, depending on the curriculum. These interactions were critical for me to learn the 
level of scientific understanding amongst the students and for the students to engage with me as a 
scientist.  When I presented material to Dave’s classes, I tried to integrate my research with their 
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course material. For example, I explained how we quantify proteins in the lab as they were 
learning to detect the presence of proteins.  I also tried to expand upon Dave’s standard teaching 
techniques, such as showing them a 3D crystal structure of salivary amylase when they were 
conducting a lab on this enzyme.  The students really connected with this interactive medium 
because they could rotate and move the crystal structure model.  We also related this to their 
study of protein secondary structures which was typically taught using 2D drawings on paper. 
I not only expanded upon their classroom material, but also asked them to engage in my 
experimental coursework, in an effort to show them ongoing learning.  For example, while they 
were learning about light microscopes, I was learning to use a two-photon microscope for a 
class.  So I taught them in general terms what two-photon microscopy was, and then asked them 
to suggest what I should look at under the microscope. The class decided it should be a bug with 
wings. I then brought in pictures of the microscope set-up , images of the bug and shared my 
experiences with them of both the excitement and disappointment in the images.  This really 
demonstrated how much easier it was to get students interested in topics that I also had a vested 
interest in, whether due to my research or coursework.   
Wolbachia curriculum in Environmental Science   
The Wolbachia Project called “Discover the Microbes Within!” is a nationwide program 
sponsored by the Marine Biological Laboratory designed to engage high school students in real-
world scientific research.  The research aim of the program is to analyze local insects for the 
microbe Wolbachia pipientis in order to track infected species.  The project coordinates 
workshops across the country to train teachers in the curricula and Cornell’s Institute for Biology 
Teachers (CIBT) also supports this program. Dave and I took the curriculum training through 
CIBT and brought this unique program to his Environmental Science course during the spring 
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semester.   
At the beginning of the Wolbachia program, we shared with the students how tracking 
species infected with the bacterial endosymbiont Wolbachia pipientis relates to human health.  
Currently, W. pipientis is making headline news as a potential “mosquito vaccine” towards 
reducing the transmission of dengue fever which is an infectious tropical disease. W. pipientis is 
considered a “reproductive parasite” because it alters sexual reproduction, but it is also able to 
make mosquitoes immune to the dengue virus and is passed on to progeny. Thus by releasing a 
population of infected mosquitoes, the local population of mosquitoes carrying dengue can be 
significantly reduced [109]. Additionally, W. pipientis is known to infect nematodes which can 
cause heartworm in dogs and river-blindness in human beings.  These real-world implications of 
W. pipientis were used to excite the students for the program and to give them an idea of how 
seemingly obscure research can contribute to health and medicine.  
The Wolbachia project provided the students an opportunity to collect insects and classify 
them using a web based identification key.  They then extracted DNA from the insects and 
performed a polymerase chain reaction (PCR) to amplify the Wolbachia pipientis DNA.  Finally 
they evaluated their PCR products using gel electrophoresis.  This unit was specifically geared 
toward the Environmental Science curriculum and was a unique opportunity for the students to 
engage in a citizen science project. 
Forensic Science DNA Fingerprinting curriculum 
This unit was organized over five class periods with two introductory lessons, two 
experimental lessons and one conclusion lesson.  The overall goal of the unit was to reinforce 
genetic concepts by allowing the students to perform DNA-based molecular biology experiments 
to determine which suspect was at the scene of a crime.  After learning about DNA and gel 
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electrophoresis, the students were able performing polymerase chain reaction (PCR) to amplify 
the DNA collected at the “crime scene”. In Forensic work, PCR amplification of DNA allows us 
to look at loci with alleles that differentiate people.  These loci, known as short tandem repeats 
(STRs), are also used by the FBI to identify criminals. We also discussed the power of 
discrimination, highlighting that looking at up to 13 different loci is required to identify one 
individual from millions of people. The curriculum and handouts used for this program are 
included as Appendices A and B, respectively. 
During this curriculum I noticed how the students who had previously been disengaged 
became truly intrigued in the new material and experimental lab set-up.  I was surprised to find 
that the students, who had historically struggled to grasp concepts, became more engaged, as 
evidence by their willingness to ask questions.  The students were also very attentive and wanted 
to ensure they were doing all the hands-on techniques correctly.  Although the results from the 
experiments were a little unclear (literally fuzzy pictures) the students completed their 
worksheets for the unit and asked questions regarding topics they were unsure about.  Overall it 
was a great experience and very rewarding to see the students engage in a technical topic full of 
scientific techniques used in both molecular biology and forensic analyses. 
Student Evaluation 
In an attempt to analyze how the DNA Fingerprinting unit influenced the students, I utilized a 
survey before and after the unit that included both a test of student attitudes and content in the 
genre of genetics (Appendix C). Questions were taken directly from two standardized tests: the 
TOSRA (Test of Science-Related Attitudes) subsets on Social Implications of Science, Adoption 
of Scientific Attitudes and Attitude to Scientific Inquiry and a subset of questions from Dr. Susan 
Elrod’s Genetics Concepts Inventory (GCI) [110, 111].  I selected questions from the GCI based 
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on the material I knew we would touch upon in the unit.  However, in comparing the before and 
after surveys, no significant improvements were made in the content of genetic concepts.  In 
retrospect, I realized while the questions drew on fundamental genetic concepts, the material was 
not specifically covered during my unit and therefore would require the students to refer back to 
previous biology courses.  In comparing the TOSRA subsets before and after, a slight increase in 
attitudes towards science was seen in all areas, as shown below.  The data was averaged over 
seventeen students who took both the pre- and post-surveys (with parental permission).  
Questions asked in a negative way were corrected for as suggested by the TOSRA handbook 
[111]. While the improvement of attitudes seen is not statistically significant, it could reveal the 
overall influence of a positive experience on the students’ inclinations toward science.   
 
 
Figure 6.1 Test of Science-Related Attitudes. Seventeen students from the Forensic Science 
course participated in pre- and post-curriculum surveys evaluating their attitudes related to 
science.  The scores from these surveys were clustered into topics including the social 
implications of science, adoption of scientific attitudes and attitude of scientific inquiry.  In these 
three subsets, a marginal improvement of attitude was detected.   
 
Discussion 
The goal of the National Science Foundation in supporting graduate students through GK-12 
fellowships is to two-fold.  First, graduate students are given a unique opportunity to teach 
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science and communicate at an educational level unlike standard training opportunities such as 
university teaching assistance appointments.  Secondly, by engaging in K-12 education, graduate 
students have an opportunity to encourage young burgeoning students in STEM content.  The 
entire program is built to be a two-way street, where K-12 students get excited about science and 
graduate students learn to teach and communicate.  In my GK-12 experience, I benefited greatly 
by the unobserved component of this system, my high school teacher Dave Syracuse. Dave is a 
very enthusiastic and engaging science teacher who daily tried to excite his students in scientific 
materials.  As such, I believe I benefited far more from this GK-12 exchange. 
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APPENDIX A – DNA Fingerprinting curriculum 
Forensic DNA Fingerprinting 
Subject:  Forensic Science/Advanced Biology 
Level:  High School 
Standards:  New York State- Living Environment  
Standard 1- Analysis, Inquiry and Design 
Standard 4.2- Genetic Inheritance, 4.3- Organisms change over time, 
4.4- Continuity of Life 
Schedule:  5 days (1 content, 3 experimental & 1 wrap-up) 
 
 
Objectives: 
 
Students will understand the process 
of synthetic DNA replication by 
polymerase chain reaction.  They 
will also understand agarose gel 
electrophoresis and the capability to 
separate DNA according to its size.  
 
Students will: 
 
• Use their understanding of 
electrophoresis to determine the 
charge of dyes based on their 
separation. And to determine the 
dyes in a mixed unknown. 
 
• Implement the process of 
Polymerase Chain Reaction by 
mixing the necessary 
components and running the 
reaction on a thermal cycler. 
 
• Analyze their PCR samples by 
running them on an agarose gel 
electrophoresis to determine 
which suspect was at the crime 
of the scene. 
 
 
Vocabulary: 
 
Polymerase Chain Reaction (PCR) 
DNA Gel Electrophoresis 
Materials: 
• Student handouts (daily) 
• 20uL adjustable pipettes P20 (student use) 
• 200uL adjustable pipette P200 (instructor use) 
• Gel electrophoresis tanks 
• Power supply 
• Biorad Crime Scene Investigator PCR BasicsTM 
Kit (#166-2600EDU) 
• Marking pens (sharpies) 
• Distilled water 
• Water bath 
• Microcentrifuge 
• Thermal cycler 
• Biorad Small Electrophoresis Reagent Pack 
(#166-0450EDU) 
• Food colored 10% glycerol solutions (optional 
day 2) 
• Dyes for migration study (optional day 2)- 
available from Frey’s (95-0420-016) 
• Eppendorfs (optional day 2) 
• SybrSafe & Blue Light Box (optional alternative 
FastBlast blue stain from kit) 
(See Classroom Procedure for daily lists) 
 
Safety: 
 
Gloves should be worn at all times in order to 
avoid contaminating samples and to prevent 
contact with bases and EDTA (in gel & 
buffer).   
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Day 1: Introduction to PCR and Electrophoresis (42 minute lesson)   
 
Objectives (Content/Process): Students will be able to explain in their own words principles 
behind PCR and electrophoresis.  They will also be able to plan an electrophoresis experiment, 
and why it would be pertinent in a scientific setting.   
 
Materials:    
• Handouts about DNA structure, PCR and electrophoresis 
• DNA replication video, available on Youtube: 
http://www.youtube.com/watch?v=teV62zrm2P0&feature=related) 
• Nickelodeon guts video, available on Youtube: 
http://www.youtube.com/watch?v=NcxjUq6m8Tg&feature=related 
o Clips at 5:40 & 6:24 minutes showing “elastic jungle” which gives a visual parallel to 
DNA traveling through an agarose gel (larger is slower) 
 
Lesson:   
1. What has to happen for DNA replication to occur?   
a. Open the two strands to get access to the bases ATC&G – topoisomerase unwinds 
the DNA and helicase separates the two strands 
b. Single strand binding proteins line up along the DNA to hold the two strands 
apart 
c. Now we need to add new bases to the separated strands, this is initiated by a RNA 
primer which is added by an enzyme called primase, the RNA is eventually 
replaced by DNA though 
d. DNA extension can then continue after the primer and is done by DNA 
polymerase, one by one nucleotides are aligned and added at the 3’ end… what 
about the other side of the fork? 
e. The two strands are called leading and lagging strands, the leading strand has 
nucleotides added directly, the lagging strand has what are called Okazaki 
fragments which are then “glued” together by DNA ligase 
f. Show YouTube video 
2. So why is replication important to forensics?  We need lots of DNA to identify an 
individual, but often there are trace amounts at the scene of a crime 
3. Question to the students: What can scientists do with DNA? 
a. Other questions…  why do they want to work with DNA? What is the significance? 
b. Cloning – make synthetic DNA or move DNA from one organism to another 
c. Genetic engineering – alter genes, therefore proteins, therefore functioning 
d. Therapeutic uses – possible therapeutic uses include gene therapy or biological 
therapeutics such as proteins (possibly engineered genetically) 
4. Techniques for working with DNA – used by both research and forensic scientists 
a. PCR: polymerase chain reaction 
i. Allows amplification of a specific region on DNA – why would it be 
valuable to copy DNA? 
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1. 1 copy of DNA -> millions of copies 
2. Increased number of copies exponentially 
3. Cheap and easy technique, therefore revolutionized molecular 
biology 
ii. Required Materials: 
1. Taq polymerase -  from Thermus aquaticusa thermophilic bacteria 
from which it was isolated in 1965; optimum temperature for 
activity is 75-80˚C 
2. dNTPs – deoxyribonucleotide triphosphates 
3. buffer (w/Mg required cofactor of polymerase) 
4. primers – 18-22bp 
5. template DNA 
iii. 3 steps of PCR: 
1. Denaturation – 2 strands separate at 90-95C 
2. Annealing – primers anneal to template strands at 55-70C (depends 
on the primer length and composition, Tm indicates temp at with ½ 
is duplex and ½ is single stranded) 
3. Extension – polymerase adds A, T, C, G at 72C 
b. Electrophoresis 
i. Gain interest by showing video of Nickelodeon Guts bungee obstacle 
course 
ii. Motion of particles relative to a fluid under the influence of a uniform 
electric field 
iii. Movement is cause by the presence of a charged interface between the 
particle surface and the surrounding fluid 
iv. In a negative to positive field, which way would DNA travel?  To the 
positive end 
v. By adding a porous medium, agarose gel, the size of the DNA now 
significantly affects the migration of the negatively charged DNA 
vi. Small pieces travel faster than large pieces of DNA 
vii. This allows the separation of different sized pieces of DNA 
viii. Main principles of agarose gel electrophoresis  
1. Negative charge, size of fragment, concentration of gel 
2. Voltage – how quickly do the charged particles move 
3. Buffer – conductive material 
Check for comprehension:  Ask students to draw an electrophoresis setup 
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Day 2: Techniques of Electrophoresis (42 minute lesson)      
 
Objectives (Content/Process): Students will be able to setup a DNA gel electrophoresis and 
properly handle all required equipment including a gel rig, pipette, samples, and voltage source.   
 
Materials:    
• P200 to aliquot samples (teacher) 
• 20 P20s for students  
• Pipette tips & boxes 
• Parafilm 
• Dyed glycerol solution 
• Colored tape 
• Precast 1% agarose gels (one per group) with combs in the middle (200mL gel @ 1%) 
• Dyes for migration:  
o solution A & B (mixture of dyes as unknowns)  
o xylene cyanol (538.6g/mol), negative ~4kb in 1% 
o orange g (452.4g/mol), negative ~ 50bp 
o methyl green (458.5g/mol), positive 
o bromophenol blue (669.96g/mol), positive ~500bp 
 
Experimental Lab:   
1. Pipetting techniques 
a. First determine the volume you want to pipette and set the dial  
b. Pipettes have two stops, the first is the correct volume, the second adds a burst of 
air to eject any remaining solution 
c. Go to the first stop when you push air out before pipetting up  
d. Pipette up slowly to ensure that no liquid gets up into the pipette – this can ruin 
the seal 
e. When pipetting out, use the second stop to get the last drop out 
f. Pipette colored water drops of varying volumes onto parafilm (5, 10) 
g. Mixing: pipette slowly and only go to first stop 
h. Mix your two favorite colors 
i. Check the bottom of your pipette to make sure no color is on the bottom, if there 
is, you’ve pipetted too quickly or too much! 
2. Running a gel with dyes to see migration 
a. One precast gel per group 
b. Set up the gel in the rig and remove the comb 
c. Dilute buffer from 10x to 1x and pour into gel tank 
d. Load each well with 10uL of dye,  using a separate tip for each well, making sure 
to write down the order of your samples being loaded 
e. Run the gel at 200V for quick migration (~15min) 
f. Evaluate dye migration of controls compared to the unknown samples 
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Check for comprehension:  What were the dyes in the unknown solutions? What do you expect 
to see from a DNA fingerprinting gel?  What will be the same as this dye gel and what will be 
different? 
 
 
 
Day 3: Polymerase Chain Reaction (42 minute lesson)      
Objectives (Content/Process):  Students will be able to explain why PCR is used in science and 
how it works.  Also they will know all the ingredients required for a PCR to work and the three 
steps of the reaction. 
 
Materials:    
• P200 & P20 for teacher to aliquot samples 
• P20s for students  
• Tubes – with DNA aliquots and MasterMix + Primer (MMP) premixed 
• Tube racks 
• Small tube racks 
• Pipette tips 
• Tube markers - sharpies 
• Ice boxes 
• Thermal cycler programmed 
• Handout for students with protocol and questions 
 
Experimental Lab:   
1. Review Theory: 
a. Required Materials: 
i. Taq polymerase -  from Thermus aquaticusa thermophilic bacteria from 
which it was isolated in 1965; optimum temperature for activity is 75-
80˚C 
ii. dNTPs – deoxyribonucleotide triphosphates 
iii. buffer (w/Mg required cofactor of polymerase) 
iv. primers – 18-22bp 
v. template DNA 
b. 3 steps of PCR: 
i. Denaturation – 2 strands separate at 90-95C 
ii. Annealing – primers anneal to template strands at 55-70C (depends on the 
primer length and composition, Tm indicates temp at with ½ is duplex and 
½ is single stranded) 
iii. Extension – polymerase adds A, T, C, G at 72C 
2. Label all tubes – MMP, CS, A, B, C, D + group identifier  
3. Keep all samples cool on ice 
4. Pipette 20uL of each DNA sample into a PCR tube, be sure to use a fresh pipette tip for 
each 
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5. Add 20uL of MMP to each tube, using a fresh pipette tip each time 
6. Close the tube and mix by flicking the tube 
7. Start thermal cycler 
a. Review 3 steps and the program of the thermal cycler 
 
Lesson:  
1. Allele Frequencies & STR loci 
a. Alleles are alternate forms of a gene, original word was allelomorph meaning 
“other form” 
b. A gene is a discrete unit of hereditary information consisting of a specific 
nucleotide sequence in DNA 
c. A gene may produce a product of RNA or protein … somewhat complex 
d. An allele describes the variance among people, we all have similar genes which 
perform the same function, but the sequence may be slightly different 
e. By looking at specific loci (locations in the genetic material) and amplifying that 
gene, alleles can be detected 
f. For example, blood typing is base on the different alleles, AB&O  
i. The ABO locus is located on chromosome 9 and has three allelic forms 
encoding two different forms of a protein called glycosyltransferase that 
bonds different sugars to the H antigen in red blood cells, the O allele has 
a mutation such that no glycosyltransferase is produced and the H antigen 
remains unmodified 
g. Some loci contain very recognizable and variable sequences called short tandem 
repeats or STRs 
h. STRs are short repeats of the same sequence : ATCA  ATCA  ATCA  ATCA 
i. What is recognizable is that the number of repeats varies from person to person 
and often within each person on their chromosomes 
j. Draw what this looks like on the board 
k. In forensic analysis often times 13 different loci will be analyzed to increase the 
power of discrimination  
l. In our PCR we have used primers that bind one loci, BXP007 and will show us 
the alleles of DNA from the crime scene and from suspects, there are 8 different 
possible alleles (15, 10, 7, 5, 4, 3, 2, 1) 
m. STRs can also be used to determine familial relationships 
Check for comprehension:  handout with questions regarding alleles and PCR 
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Day 4: Gel Electrophoresis & Analysis (42 minute lesson)     
  
Objectives (Content/Process): Students will be able to setup a DNA agarose gel electrophoresis 
and properly handle all material required. 
 
Materials:    
• 3 x 250mL, 3% agarose gels- pre-cast with SYBR Safe 
• Flask to make TAE solution in 
• Gel rigs 
• Power sources 
• Student P20 pipettes 
• Pipette tips 
• PCR samples 
• Orange G loading dye 
• Allele Ladder 
• 0.5x TAE (from 50x stock) 
• SYBR Safe blue light boxes 
• Camera 
• Handout for students with protocol and questions 
 
Experimental Lab:   
1. Centrifuge PCR tubes to get all solution in the bottom  
2. Add loading dye 10uL to each PCR mix 
3. Check orientation of gel in the gel tank 
4. Order samples for loading and write down the order 
5. Load samples individually – 20uL each 
6. Secure lid in correct orientation 
7. Turn on power supply and electrophorese gel at 200V for 20 min 
8. Look at gel after electrophoresis with blue light box and orange shield 
9. Take picture of gel 
10. Document each suspect’s allele pattern 
11. Identify suspect who was at the crime scene 
Check for comprehension:  handout with questions regarding gel electrophoresis 
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Day 5: Wrap-up/ Conclusions (42 minute lesson)      
  
Objectives (Content/Process): Ensure students understand the process of DNA Fingerprinting 
and the complexity of using this technique to accurately identify a culprit from a pool of 
suspects.  
 
Materials:    
• Pictures of gels 
• TH01 allele frequency image – from BioRad handbook p.10 
• Loci visual aid of power of discrimination  
•  
Lesson:   
• Power of Discrimination: 
o Larger the number of loci typed, the more powerful the ability to discriminate 
between individuals 
o Allele frequencies don’t follow regular mathematical patterns 
o Allele frequencies change among different populations – look at TH01 allele 
frequency graph 
o Can use the frequency of each allele to determine the frequency of a genotype 
o Example: Looking at multiple loci  
 A Caucasian suspect has STR of 16 & 17 at loci D3S1358, the frequencies 
of which are 16=0.253 and 17=0.215 in the Caucasian population 
 The frequency of this 16-17 genotype can be calculated by multiplying : 
2 x 0.253 x 0.215 = 0.109 or 1/10 people 
 1/10 people is not very convincing … let’s look at a second loci 
 Same suspect has a STR of 10-8 at loci TH01, the frequencies of which 
are 10 = 0.008 and 8 = 0.125 
 The frequency of this 10-8 TH01 genotype is : 
2 x 0.008 x 0.125 = 0.002 or 1/500 people 
 1/500 people is more convincing, but if we use both the D3S1358 and the 
TH01 locus (0.125x0.002 = 0.000218) we can say it’s found only in 1 out 
of 5,000 people 
 Note that the FBI uses 13 loci! 
• CODIS: Combined DNA Index System – maintained by FBI to help connect cases across 
states both criminal and missing persons 
• Actual complexity of loci: http://www.cstl.nist.gov/biotech/strbase/str_fact.htm 
• Mitochondrial DNA matching: for missing persons (inherited only from mother) 
therefore not unique enough for forensics 
• Power of discrimination statistics:  
 
Check for comprehension:  post-survey to see concept comprehension regarding genetic 
information such as genes, alleles and loci 
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Extension Activities: 
 See the Crime Scene Investigator PCR BasicsTM Kit Handbook which contains more materials 
for lectures (Appendix A) as well as a sample case (Appendix B) and an extension of looking at 
the power of discrimination (Appendices B & C).   
 
Supplemental Information: 
DNA in the electrophoresis gels can be visualized by FastBlast stain (overnight or in 20min) or 
using SybrSafe in the gel.  If using FastBlast stain, the evaluation of the results will not occur 
until Day 5.  Also, day 4 and day 5 should be back to back to avoid diffusion.   
 
Safety:  
General Practices: wear gloves at all times when handling buffers and solutions 
 
SybrSafe – considered non-carcinogenic, with a toxicity LD50> 5000mg/kg.  However it still 
chelates with DNA and therefore should be handled very carefully, wearing gloves at all times.  
Disposal should be arranged with an Environmental Health & Safety Office.   
 
TAE – contains Tris Base, Acetic Acid and EDTA, all of which are skin irritants and thus gloves 
should be worn at all times.  
 
Agarose –skin irritant, flush with water 
xylene cyanol – skin irritant, flush with water 
orange g – skin irritant, flush with water 
methyl green – skin irritant, flush with water 
bromophenol blue – skin irritant, flush with water 
 
 
Waste Disposal Method - All chemical disposal must be in accordance with current local, state, 
and federal regulations. 
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APPENDIX B – DNA Fingerprinting handouts DNA Structure 
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DNA Fingerprinting Techniques Polymerase Chain Reaction (PCR): Materials:  1) Taq DNA polymerase 2) dNTPs (deoxyribonucleotide triphosphates) – A, T, C, G 3) primers (18-22bp) 4) template dsDNA (double stranded DNA) 5) buffer solution Process:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   25 rounds -> 225 = 33,554,432 copies of DNA! 
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DNA Agarose Gel Electrophoresis:  dsDNA       small fragments of varied size      (-) negative charge (-)   wells for DNA samples         agarose matrix gel matrix     (+) positive charge (+)  
DNA electrophoresis results: 
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Crime Scene: Highway Motel Rm#13  The motel manager hears loud voices, a woman screams, and a shot rings out.  The manager runs to the window in time to see the receding lights of a car leaving in a hurry.  The door to room #13 hangs open. The manager runs to the open door, to see a man lying face down in a pool of blood.  He calls 911.  The police arrive, and begin to examine the crime scene.  An apparent homicide, but with no obvious clues as to who committed the crime.  Or… ? 
What kinds of human DNA sequences are used in crime scene investigations?  There are ~3billion basepairs in the human genome – greater than 99.5% don’t vary between different human beings.  However, a small percentage of the human DNA sequence (<0.5%) does differ, and these are the special polymorphic (“many forms”) sequences used in forensic applications.  By universal agreement, DNA sequences used for forensic profiling are “anonymous”; that is, they come from regions of our chromosomes (also called loci) that do not control any known traits and have no known functions.  Loci are basically genetic addresses or locations.  A single locus may have different forms or types; these different forms are called alleles.  A locus may be bi-allelic, having only two different forms, or it may be polymorphic, as described above. The DNA sequences used in forensic labs are non-coding regions that contain segments of Short Tandem Repeats or STRs. STRs are very short DNA sequences that are repeated in direct head-to-tail fashion.  The example below shows a locus (known as TH01) found on chromosome 11; its specific DNA sequence contains four repeats of [TCAT].  …CCC TCAT TCAT TCAT TCAT TCA… For the TH01 STR locus, there are many alternate polymorphic alleles that differ from each other by the number of [TCAT] repeats present in the sequence.  Although more than 20 different alleles of TH01 have been discovered in people worldwide, each of us still has only two of these, one inherited from our mother and one inherited from our father.  For example as shown below, suspect A has one allele with 5 repeats, and one allele with 3 repeats, giving a DNA profile for the TH01 locus of 5-3.   Suspect A’s DNA type for the TH01 locus: CCC         AAA                   CCC            AAA Suspect B’s DNA type for the TH01 locus: CCC     AAA CCC          AAA    
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Imagine a scenario in which Suspect A and Suspect B are accused of being involved in a love triangle and committing the murder of a third person in the Highway Motel Room #13; the person who actually pulled the trigger is unknown.  In addition to DNA samples from the crime scene, the forensic specialist will isolate DNA from suspects, victims, and others present to genotype as controls.  Using PCR-based analysis, the samples will be examined at 13 different genetic loci, using software to interpret the results from the amplification products.  In real crime scene analysis DNA profiling is performed at many loci to improve the power of discrimination of the testing.  The power of discrimination is the ability of the profiling to tell the genetic difference between different individuals.  The larger the number of loci profiled, the more powerful the ability to discriminate. You are about to conduct real world forensic DNA profiling.  As a crime scene investigator, you will use the polymerase chain reaction (PCR) and agarose gel electrophoresis to analyze the DNA samples obtained from a hypothetical crime scene and four suspects.  Your job is to identify the perpetrator.  A genotype is the particular set of genetic markers, or alleles, in a DNA sample.  Every person’s genotype is their own uniquely personal genetic barcode.  In this experiment, you’ll be revealing the genetic barcodes of several individuals by looking at a single locus BXP007 and looking for whodunit!  
Polymerase Chain Reaction: 
Materials:  
• Ice bath containing tubes 
• Master Mix + primers (MMP, blue liquid) 
• Tubes of DNA (Crime Scene and Suspect A-D DNAs) 
• PCR tubes (small tubes) 
• Marking pen 
• P20 pipette 
• Pipette tips 
 
Protocol: 1) Keep tubes on ice during the entire procedure.  Only remove them to remove or add a solution.   2) Label the PCR tubes CS, A, B, C and D and include your group name as well.   3) Set your pipettes to 20µL and transfer 20µL of MMP into each of your tubes. 4) Next transfer 20µL of template DNA into the appropriately labeled tube.  For example, transfer 20 µL from the Crime Scene tube to the tube labeled ‘CS’. 
Important: use a fresh pipette tip for each DNA sample! 5) The solution in your PCR tubes should be blue now.  Be sure to cap the tubs securely and keep them on ice.   6) When instructed to do so, place your tubes in the thermal cycler.   7) Write down the cycle that will be used in the thermal cycler.   
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Questions: 1) What kind of materials obtained from a crime scene might contain DNA?     2) What might you see if you ran a DNA sample extracted from evidence on a gel before PCR?  Why do you need to perform PCR on DNA evidence?     3) What is a genotype?     4) What is the difference between an allele and a locus?     5) Why do forensic labs analyze non-coding DNA and not genes?      6) What components do you need to perform PCR and why do you need each component?     7)  What steps make up a PCR cycle, and what happens at each step? 
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Crime Scene: DNA evaluation   You have completed your PCR amplification.  However, at this point, you can’t actually tell whether or not you have PCR products.  To do this, you must sort your PCR products using gel electrophoresis and then visualize them using a DNA stain.  Since DNA is negatively charged, it can be separated using an electric current.  In fact, electrophoresis means “carry with current”.  In agarose gel electrophoresis, DNA is placed in solidified agarose, which forms sieves containing pores that vary in size depending on the concentration of the agarose.  The higher the concentration of agarose, the smaller the pore size, and the longer it takes for larger molecules to move through.  This is particularly useful when you want to compare DNA molecules of different sizes contained in the same sample.  Movement through the gel occurs when an electric current is applied across the gel.  Since the gel is immersed in buffer, the current will travel through the buffer and gel, carrying the negatively charged DNA with it toward the positive anode.    In addition to your PCR products, you will also be running a DNA Allele Ladder (shown below) that represents all the possible alleles at the BXP007 locus.  This is a reference, or marker, that you can compare your PCR reactions to so you can judge their relative sizes and their identities.  These are the standard sizes of all the alleles known to occur at this locus.  There are 8 possible alleles, with the largest at the top of the gel and the smallest at the bottom.  The sizes are, from top to bottom, 1500, 1000, 700, 500, 400, 300, 200 and 100 base pairs (bps).  Allele names are based on the fragments that result from an individual DNA sample.  For example, if a PCR produces 500bp and 200bp fragments, the sample has a genotype that corresponds to alleles 5 and 2 on the allele ladder.  We would say that the genotype for this sample is 5-2.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BXP007 
 15 
10 
7 
5 
4 
3 
2 
1 
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DNA Gel Electrophoresis: 
Materials:  
• Ice bath containing PCR samples 
• Allele ladder 
• Loading dye 
• P20 pipette 
• Pipette tips 
• Pre-cast 3% agarose gel 
• TAE running buffer 
• Gel tank 
• Power source 
• Light box 
• Gloves – wear gloves at all times! 
 
Protocol: 8) Set-up your gel electrophoresis tank.  Be sure the wells are over the red tape in the box and that the DNA will migrate toward the positive electrode (red cable). 9) Fill your gel electrophoresis tank with running buffer. 10) Add 10µL of Orange G loading dye (from the tube labeled ‘LD’) to each PCR reaction tube and mix well by pipetting.  Important: use a fresh tip each time! 11) Load 20µL of the allele ladder into the first lane.  Then load 20µL of each sample into the following lanes.  Each sample gets its own lane and be sure to use a fresh tip 
each time.  Write down the order you load your samples in on the table below:  
Lane Sample Load Volume 1 Allele Ladder 20µL 2   3   4   5   6   12) Run your gel at 200V for 20 minutes.  Do not let the orange dye migrate out of the gel. 13) When the gel has finished running, remove it from the electrophoresis tank and place it on the blue light box.  The DNA stain that is in the agarose gel is called SybrSafe.  It binds DNA by interacting with the NH group (amine) and fluoresces only upon binding.  SybrSafe is excited at 502nm and emits at 540nm, so we use a blue light to visualize the DNA.   14) Take a picture to record your findings and also record the suspect genotypes under question #5. 
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Questions:  8) Why does DNA move through an agarose gel?     9) What are the two techniques used to create a DNA profile (used over the past two experiments)? What function does each perform?      10) What is an Allele Ladder? What is its function in DNA profiling?      11) What is required to visualize DNA following electrophoresis?        12) What are the genotypes for each of the suspects and which one matches the genotype from the crime scene? 
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APPENDIX C – DNA Fingerprinting questionnaire 
Identification #: _______________ 
 
Directions: 
1. This survey has two separate sections. Each section has its own set of directions. 
2. The first section of this survey contains a number of statements about science.  You will 
be asked what you think about these statements.  There are no “right” or “wrong” 
answers.  Your opinion is what is wanted.   
3. For each statement, draw a circle around the specific numeric value corresponding to how 
you feel about each statement. Please circle only ONE value per statement.  
 
5 = Strongly Agree (SA) 
4 = Agree (A) 
3 = Uncertain (U) 
2 = Disagree (D) 
1 = Strongly Disagree (SD) 
 
 
Statement SA         A         U         D         SD 
 
1.  Money spent on science is well worth spending. 
 
5            4          3          2           1 
2.  I would prefer to find out why something happens by doing an 
experiment than be being told.  
5            4          3          2           1 
3.  I enjoy reading about things that disagree with my previous 
ideas. 
5            4          3          2           1 
4.  Science is man’s worst enemy. 
 
5            4          3          2           1 
5. Doing experiments is not as good as finding out information 
from teachers.  
5            4          3          2           1 
6. I dislike repeating experiments to check that I get the same 
results. 
5            4          3          2           1 
7. Public money spent on science in the last few years has been 
used widely. 
5            4          3          2           1 
8. I would prefer to do experiments rather than to read about them. 5            4          3          2           1 
9. I am curious about the world in which we live. 
 
5            4          3          2           1 
10. Scientific discoveries are doing more harm than good. 
 
5            4          3          2           1 
11. I would rather agree with other people than do an experiment to 
find out for myself. 
5            4          3          2           1 
12. Finding out about new things is unimportant. 
 
5            4          3          2           1 
13. The government should spend more money on scientific 
research. 
5            4          3          2           1 
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Statement SA         A         U         D         SD 
 
14. I would prefer to do my own experiments than to find out 
information from a teacher. 
5            4          3          2           1 
15. I like to listen to people whose opinions are different from 
mine. 
5            4          3          2           1 
16. Too many laboratories are being built at the expense of the rest 
of education. 
5            4          3          2           1 
17. I would rather find out things by asking an expert than by doing 
an experiment. 
5            4          3          2           1 
18. I find it boring to hear about new ideas. 
 
5            4          3          2           1 
19. Science helps to make life better. 
 
5            4          3          2           1 
20. I would rather solve a problem by doing an experiment than be 
told the answer. 
5            4          3          2           1 
21. In science experiments, I like to use new methods which I have 
not used before. 
5            4          3          2           1 
22. This country is spending too much money on science. 
 
5            4          3          2           1 
23. It is better to ask a teacher the answer than to find it out by 
doing experiments. 
5            4          3          2           1 
24. I am unwilling to change my ideas when evidence shows that 
the ideas are poor. 
5            4          3          2           1 
25. Science can help to make the world a better place in the future.  
 
5            4          3          2           1 
26. I would prefer to do an experiment on a topic than to read about 
it in science magazines. 
5            4          3          2           1 
27. In science experiments, I report unexpected results as well as 
expected ones. 
5            4          3          2           1 
28. Money used on scientific projects is wasted. 
 
5            4          3          2           1 
29. It is better to be told scientific facts than to find them out from 
experiments.  
5            4          3          2           1 
30. I dislike other peoples’ opinions.  
 
5            4          3          2           1 
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Section Two: 
Directions:  
1. The following questions are multiple choice (one answer) unless indicated that there are 
possibly multiple answers (MA).   
2. Circle the answer that you think is correct and answer all the questions to the best of your 
ability. 
 
1. (MA) What is the chemical composition of DNA? 
protein    amino acids  
nucleotides   nucleus 
genes    alleles 
traits    chromosomes 
 
2. During DNA replication, what serves as the template for synthesis of a new strand? 
one of the two strands of the double helix 
each of the two strands of the double helix  
random pieces of the both strands of the double helix 
 
3. After DNA replication of a DNA double helix molecule, two DNA double helices result. 
Which of the following statements best describes the composition of the two resulting double 
helices? 
Both strands in one of the two helices are new and both strands in the other helix are old 
In each of the two helices, one of the two strands is new 
Random pieces along each strand of both helices are newly synthesized 
 
4. What are most genes made of? 
protein    alleles 
RNA    cells 
DNA    amino acids     
chromosomes   nucleus 
 
5. (MA) In which of the following cell types within your body are genes found? 
brain    heart 
blood    reproductive (e.g. gametes) 
eye    all of the above 
 
6. If an organism is diploid, and has 16 chromosomes, how many sets of homologous 
chromosomes does it possess? 
32 
16 
8 
4 
2 
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7. Which of the following is true of homologous chromosomes? 
They aren’t usually the same size and shape 
They are inherited from different parents 
They do not pair during meiosis 
They contain different set of genes 
They contain identical DNA sequences 
 
8. What is an allele? 
part of a gene (e.g., half of a gene) 
one of two genes in a diploid organism 
an alternate form of a gene 
a region of a chromosome where a gene is located 
a chromatid or chromosome 
 
9. If a skin cell starts with 24 chromosomes, what number of chromosomes will it have at the end 
of cell division? 
12 
24 
36 
48 
 
10. (MA) Which of the following cell types contain genetic information for the eye color of an 
organism? 
brain   heart   
blood   gamete 
eye 
 
11. Genetic recombination refers to 
relationship between genes on the same chromosome 
independent assortment of alleles during meiosis 
the process of mutation 
co-segregation of genes during meiosis 
splicing of RNA molecules 
sorting of alleles into new combinations 
relationship between alleles of a gene 
 
12. What is meant by the ‘genetic code’? 
the differences in DNA that make individuals unique 
the specific sequence of DNA that codes for an amino acid 
the order of DNA bases within an individual 
the order of RNA bases that code for a protein 
 
13. Which of the following molecules are the products of translation? 
DNA    cells 
amino acids   chromosomes 
messenger RNAs 
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14. Which of the following molecules are the products of transcription? 
DNA 
amino acids 
messenger RNAs 
proteins 
cells 
chromosomes 
 
15. What is the term for the physical constitution of an organism? 
genotype 
dominant trait 
character type 
phenotype 
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